Taking the Stage: Scientific Conferences

Underline: KUCC Members
Underline & Bold: KUCC Members that Presented

April 7, 2023

SESSION PO.CL01.05 - Spatial Proteomics and Transcriptomics
1:30 PM - 5:00 PM     
1136 / 3 - Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)
V. Mathew Thomas, B. Chigarira, G. Gebrael, C. Chehade, A. Narang, N. Sayegh, N. Tripathi, Y. Jo, C. Tandar, A. Srivastava, R. Ji, E. Dal, G. Fortuna, H. Li, B. L. Maughan, U. Swami, N. Agarwal

SESSION PO.PR01.03 - Epidemiology 
1:30 PM - 5:00 PM     
769 / 5 - Incorporating a cross-ancestry polygenic risk score into a clinical model improved breast cancer risk prediction in women with pathogenic variants
P. Tshiaba, M. Sun, D. Ratman, J. N. Weitzel, P. Shah, M. Rabinowitz, A. Kumar, K. Im

SESSION PO.PS01.10 - Environmental and Occupational Risk Factors, Infection, and Aging
1:30 PM - 5:00 PM     
844 / 17 - DNA methylation-derived immune cell profiles and risk of cancers in Black participants in the ARIC Study
C. S. Semancik, N. Zhao, D. Koestler, E. Boerwinkle, J. Bressler, K. Kelsey, E. A. Platz, D. S. Michaud

SESSION PO.TB04.04 - Membrane, Biophysical, and EMT Aspects of Motility/Metastasis
1:30 PM - 5:00 PM     
197 / 6 - The GPR52-MCAM axis as a novel regulatory mechanism of breast cancer cell clustering and metastatic potential 
S. Z. Hanif, C. C. Au, I. Torregroza, B. Bhinder, L. Dow, O. Elemento, T. Evans, K. A. Brown

SESSION PO.CL01.05 - Spatial Proteomics and Transcriptomics
1:30 PM - 5:00 PM     
1163 / 30 - Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment
A. C. Soupir, M. T. Hayes, T. C. Peak, O. E. Ospina1, N. H. Chakiryan, A. E. Berglund1, P. A. Stewart, J. Nguyen, C. M. Moran-Segura, N. L. Francis, P. M. Ramos-Echevarria, J. Chahoud, R. Li, K. Y. Tsai, J. A. Balasi, Y. Caraballo-Perez, J. Dhillon, L. A. Martinez, W. E. Gloria, N. Schurman, S. Kim, M. Gregory, J. J. Mule, B. L. Fridley, B. J. Manley

SESSION PO.TB06.01 - Developmental Origins and Drivers of Pediatric Cancer
1:30 PM - 5:00 PM      
141 / 13 - A human induced pluripotent stem cell model of KMT2A rearranged leukemia
E. Guest, M. Vacek, J. Nemechek, I. Pushel, B. T. Thornton, M. Leyda, M. S. Farooqi, J. M. Perry, J. L. Vivian

SESSION PO.BCS01.01 - Application of Bioinformatics to Cancer Biology 1
1:30 PM – 5:00 PM
876 / 20 - spatialGE: Empowering researchers to study the tumor microenvironment leveraging spatial transcriptomics
O. Ospina, R. Manjarres-Betancur, G. Gonzalez-Calderon, A. C. Soupir, I. Smalley, K. Tsai, J. Markowitz, A. Berglund, X. Yu, B. L. Fridley

SESSION MS.TB04.01 - Metastasis
3:00 PM - 5:00 PM     
Room 29 - Upper Level - Convention Center
Track(s): Tumor Biology, Tumor Microenvironment
Introduction; Chairperson, Danny R. Welch, University of Kansas Cancer Center, Kansas City, KS

April 8, 2024

SESSION PO.BCS01.12 - New Algorithms, Software, and Models
9:00 AM - 12:30 PM     
2338 / 16 - Benchmarking long- and short-read somatic structural variation callers using a multi-technology panel of six tumor/normal cell lines
A. Keskus, A. Bryant1, T. Ahmad, A. Donmez, I. Rodriguez, N. Rossi, Y. Xie, B. Yoo, R. Milano, H. Lou, J. Park, J. Gardner, B. McNulty, K. Miga, M. Dean, M. Farooqi, B. Paten, M. Kolmogorov

SESSION PO.IM01.02 - Immune Checkpoints and Inhibitory Molecules 1
9:00 AM - 12:30 PM     
1352 / 3 - Computational design of a cyclic peptide that inhibits the CTLA4 in T cells and the growth of lung carcinoma in mice
R. Thakkar, D. Upreti, S. Ishiguro, G. Magnin, K. Sudasinghe, A. Hall, S. DeVader, M. Tamura, J. Comer

SESSION PO.IM02.03 - Inflammation and Cancer in Metastasis
9:00 AM - 12:30 PM     
1399 / 19 - The role of CCN5 in regulation of tumor-infiltrating lymphocytes (TILS) in triple-negative breast cancer (TNBC) cells 
U. Biswas, A. Kambhampati, N. Haideri, A. De, S. Upadhyay, S. Banerjee, S. Banerjee

SESSION PO.MCB03.01 - Cell Signaling Components as Therapeutic Targets
9:00 AM - 12:30 PM     
1667 / 14 - The role of CCN1 in mutant K-RAS addiction in pancreatic cancer
A. Kambhampati, A. De, I. Haque, S. Banerjee, S. K. Banerjee

SESSION PO.ET09.06 - Novel Targets and Pathways
9:00 AM - 12:30 PM     
Section 29
2086 / 10 - Effect of XPO1 inhibition on colorectal cancer tumorigenesis
A. E. Evans, D. A. Dixon

SESSION PO.MCB08.02 - Genomic Characterization of Cancers and Cancer Subgroups
9:00 AM - 12:30 PM     
1763 / 18 - Long-read sequencing of pediatric leukemia identifies clinically relevant genomic rearrangements
B. Yoo, A. Keskus, C. Bi, L. Lansdon, T. Ahmad, I. Pushel, A. Walter, M. Gibson, E. Guest, T. Pastinen, M. Kolmogorov, M. S. Farooqi

SESSION PO.MCB09.02 - Metabolic Pathways 2
9:00 AM - 12:30 PM     
1783 / 5 - Understanding lipogenesis in bladder cancer
J. Leak, D. Matye, E. Abbott, B. Woolbright, J. A. Taylor III

1785 / 7 - The role of BRCA1 on metabolic pathways in an in vivo system
S. L. Hembruff, A. Dekonenko, J. Thyfault, M. Sardiu, M. Washburn, R. A. Jensen, L. M. Harlan-Williams

SESSION PO.PR02.01 - Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum
9:00 AM - 12:30 PM     
2187 / 21 - Influences of high-fat diet on tumor biology in a mouse model of colorectal cancer
A. Mahanty, C. Wallingford, R. Hammontree, M. Njoka, Z. Clark, M. Rekowski, M. Washburn, J. S. Davis

SESSION PO.BCS01.03 - Application of Bioinformatics to Cancer Biology 3
1:30 PM - 5:00 PM     
3497 / 19 - Glioma Immune Microenvironment Composition Calculator (GIMiCC): A method of estimating the proportions of eighteen key cell types from human brain tissue assayed using Illumina DNA methylation microarray technology
S. C. Pike, J. K. Wiencke, Z. Zhang, A. M. Molinaro, D. C. Koestler, B. C. Christensen, K. T. Kelsey, L. A. Salas

SESSION PO.BCS01.09 - Database Resources, Statistical Methods, and Other Tools
1:30 PM - 5:00 PM     
3562 / 22 - Comparison of spatial co-localization measures for studying the tumor immune microenvironment with application to ovarian cancer
B. L. Fridley, A. Soupir, J. Wrobel, C. Colin-Leitzinger, M. K. Townsend, A. B. Lawson, K. L. Terry, J. M. Schildkraut, S. S. Tworoger, L. C. Peres

SESSION PO.CL01.03 - Circulating Tumor Cells 1
1:30 PM - 5:00 PM     
3707 / 19 - Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
M. S. Serafini, C. Reduzzi, L. Gerratana, R. Jeselsohn, R. L. Mahtani, C. X. Ma, A. DeMichele, J. L. Meisel, K. D. Miller, Y. Abdou, E. C. Riley, R. Qamar, P. Sharma, S. Reid, H. J. Burstein, S. M. Tolaney, M. K. DeMeo, Y. Liu, E. Gauthier, Y. Ren, M. M. Regan, H. Liu, E. L. Mayer, M. Cristofanilli

SESSION PO.ET02.03 - Cancer Immunotherapy and Drug Delivery
1:30 PM - 5:00 PM    
3185 / 2 - Glatiramer acetate enhances tumor retention and mitigates systemic toxicity of toll-like receptor 9 agonists as intratumoral immunotherapy
H. Gong, D. J. Griffin, C. E. Groer, X. Wu, M. M. Abdelaziz, S. Wu, L. Xu, L. M. Forrest, C. J. Berkland

SESSION PO.MCB10.02 - microRNA- and Other Non-coding RNA-Based Translational Medicine
1:30 PM - 5:00 PM     
2998 / 15 - Regulation of epidermal growth factor receptor signaling by BRCA1-microRNA 146a network
E. Kumaraswamy, R. M. Koren Shimak, S. Gunewardena, K. L. Wendt, D. Alexander, S. L. Hembruff, R. A. Jensen

SESSION PO.PS01.07 - Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biologic Effects, and Prognosis
1:30 PM - 5:00 PM     
3424 / 8 - Assessing a DNA methylation-based telomere length estimator in individuals with a heavy smoking history
L. Grieshober, S. Graw, M. J. Barnett, G. E. Goodman, C. Chen, D. C. Koestler, C. J. Marsit, J. A. Doherty

SESSION MS.MCB08.01 - Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Hetero
2:35 PM – 2:50 PM
3928 - Genomic landscape and estimation of immune infiltration of soft tissue sarcoma histology subtypes from the ORIEN network
A. C. Soupir, O. E. Ospina, D. Hedges, J. K. Teer, M. D. Radmacher, D. M. McKean, N. Seligson, M. McCarter, B. Wilkey, G. Riedlinger, J. Groundland, B. J. Miller, B. Schneider, R. Patel, A. Rafeh-Naqash, S. Edge, B. Salhia, C. Moskaluk, M. Johns, M. L. Churchman, O. Hampton, D. Liebner, B. L. Fridley, A. S. Brohl

April 9, 2024

9:00 AM - 12:30 PM     
LB303 / 19 - Suppression of stress granule formation is a novel vulnerability imposed by mutant p53
E. Thoenen, A. Ranjan, A. Parrales, S. Nishikawa, D. Dixon, S. Oka, T. Iwakuma

SESSION PO.CL01.02 - Prognostic Biomarkers 1
9:00 AM - 12:30 PM     
5215 / 23 - Orphan noncoding RNA (oncRNA) liquid biopsy assay is prognostic for survival in patients with triple-negative breast cancer (TNBC) and residual disease
R. Yoder, J. Yen, M. Karimzadeh, J. M. Staley, I. Fernandez, A. C. Heinrich, F. Hormozdiari, J. Gregg, A. K. Godwin, I. Acerbi, R. Trivedi, B. Alipanahi, S. R. Stecklein, P. Sharma

SESSION PO.CL13.01 - Molecular Biology in Clinical Oncology: Genetics and Beyond
9:00 AM - 12:30 PM     
5060 / 14 - Role of molecular driver mutations in recurrence of early stage laryngeal cancer following narrow field definitive radiotherapy
A. Segura, E. Nissen, C. Lominska, R. Morse, D. Morgan, P. Neupane, D. Pei, D. Koestler, R. Kimple, U. Duvvuri, K. Sykes, S. Thomas, R. Nallani, L. Shnayder, K. Kakarala, E. Yilmaz, A. Bur

SESSION PO.IM02.01 - Adaptive Immunity in Tumors
2024, 9:00 AM - 12:30 PM     
3971 / 13 - Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland
E. I. Chowanec, L. R. Werner, C. R. Hagan

3981 / 23 - Immune targeting progesterone receptor in hormone receptor positive breast cancer
A. E. Wilson, J. Wei, G. Lei, X.-Y. Yang, C.-X. Liu, M. Gajda, T. Wang, C. Hagan, Z. C. Hartman

SESSION PO.MCB09.05 - Signaling Pathways That Regulate Metabolism 2
9:00 AM - 12:30 PM     
4460 / 14 - Investigating a non-canonical role for SHP2 in pancreatic ductal adenocarcinoma metabolism and response to dietary modifications
R. Walsh, J. L. Jack, A. E. Eades, B. A. Bye, M. T. Ruckert, J. Ambrose, M. N. VanSaun

SESSION LBPO.PR01 - Late-Breaking Research: Prevention, Early Detection, and Interception
1:30 PM - 5:00 PM     
LB381 / 12 - Plasma microbiota as novel biomarkers of early epithelial ovarian cancer detection
D. E. Mahoney, P. Chalise, D. Pei, R. Griffard, T. Home, H. Pathak, S. Umar, A. K. Godwin

SESSION PO.CL01.10 - Predictive Biomarkers 5
1:30 PM - 5:00 PM     
6417 / 29 - Urinary PKM2 in muscle invasive bladder cancer
D. Matye, J. Leak, E. Abbott, B. Woolbright, J. Taylor III

SESSION PO.CTP02.01 - Phase II and Phase III Clinical Trials in Progress
1:30 PM - 5:00 PM     
CT286 / 16 - TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
S. Thomas, Y. K. Hong, Y. Samhouri, J. Larkin, D. J. Olson, G. K. In, V. Atkinson, P. Lammers, A. J. S. Furness, J. Martin-Liberal, P. Terheyden, A. S. Poklepovic, R. H. Nguyen, I. Peretz, M. Butler, A. Khattak, L. Spain, E. Gaughan, M. Wilson, J. W. Dubay, A. Williams, S. Goff, G. C. Doolittle, J. Chesney, F. Finckenstein, J. Chou, X. Wu, G. Sulur, W. Shi, J. Haanen

SESSION PO.IM02.08 - Tumor-Induced Immune Suppression 2: Intrinsic Factors
1:30 PM - 5:00 PM     
5364 / 15 - Progesterone receptor modulates the antigen processing and presentation machinery decreasing MHC class I expression on tumors
J. Tinoco, L. Werner, E. Chowanec, H. Saunders, S. Xiaopeng, J. Gertz, J. Balko, Z. C. Hartman, C. Hagan

SESSION PO.MCB11.02 - Advances in Cancer Prognostication, Therapeutic Response, and Immune Biology
1:30 PM - 5:00 PM     
5596 / 20 - Exploring BRCA1-Y1853ter and potential therapeutic targets in BRCA1-BRCT mutated cancers
J. Chen

SESSION PO.TB11.06 - Tumor-Immune System Cross-Talk
1:30 PM - 5:00 PM     
5557 / 13 - Stem-like T cells maintain latent anticancer activity and underly therapy resistance
F. Tao, S. McElroy, J. Nemechek, I. Pushel, J. Szarejko, S. Khanal, T. Bradley, D. Myers, J. M. Perry

SESSION MS.EN01.01 - Molecular, Preclinical, and Clinical Endocrinology 3
2:35 PM - 2:50 PM    
Room 5 - Upper Level - Convention Center
6571 - O-GlcNAc sites on progesterone receptor are critical for its ligand independent repression of interferon signaling in breast cancer
H. I. Saunders, S. Holloran, E. Chowanec, J. Tinoco, C. Slawson, C. Hagan

April 10, 2024

SESSION PO.TB11.04 - Chemokines and Cytokines in Cancer
9:00 AM - 12:30 PM     
6803 / 8 - TRIM16 regulates IL-6 secretion in head and neck cancer-associated fibroblasts
T. Ly, B. Pickard, A. Pandey, N. Martinez-Rivera, E. Rosa-Molinar, M. Washburn, W.-X. Ding, S. M. Thomas

SESSION PO.TB11.09 - Immune Cells in the Tumor Microenvironment 2
9:00 AM - 12:30 PM     
6877 / 21 - Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death
A. Heard, L. R. Werner, E. I. Chowanec, H. Saunders, J. Tinoco, Z. C. Hartman, C. R. Hagan

6885 / 29 - Investigating a novel role of DCLK1 isoforms in colitis and colitis associated colon cancer
K. A. Yusuf, B. C. Roy, S. Anant, S. Umar

December 9, 2023

121 The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML
Session: 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology
Program: Oral and Poster Abstracts
Type: Oral
Time: 9:30 AM
Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, PhD, Raul C. Ribeiro, MD, Jeffrey E. Rubnitz, MD, PhD, Alan S Gamis, MD, MPH, E. Anders Kolb, MD, Richard Aplenc, MD, PhD, Stanley Pounds, PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, PhD

91 Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
Session: 652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Oral
Time: 9:30 AM
Location: Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Danai Dima, MD, James A Davis, PharmD, Nausheen Ahmed, MD, Aishwarya Sannareddy, MBB, Hira Shaikh, MBB, Zahra Mahmoudjafari, PharmD, Jack Khouri, MD, Gurbakhash Kaur, MD, Christopher Strouse, Jason Valent, Larry D. Anderson Jr., MD, PhD, Faiz Anwer, MD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

107 Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real-World Data
Program: Oral and Poster Abstracts
Type: Oral
Time: 10:30 AM
Location: Room 6A (San Diego Convention Center)

Swetha Kambhampati, MD, Nausheen Ahmed, MD, Mehdi Hamadani, MD, Soyoung Kim, PhD, Michael T. Hemmer, MS, Natalie S. Grover, MD, Mazyar Shadman, MD, MPH, Amer Beitinjaneh, MD, MPH, MSc, Elizabeth Lihua Budde, MD, PhD, James Gerson, MD, Caron A Jacobson, MD, MMSc, Frederick L. Locke, MD, Dwivedy S. Nasta, MD, Michael L. Wang, MD, Wen-Kai Weng, MD, PhD, Jiali Yan, MS, Ana Nunes, PharmD, David Dalton, PharmD, James J. Wu, MPH, MSc, Amina Abdeldaim, MD, MPH, Zhen-Huan Hu, MPH, Marcelo Pasquini, MD, MS and Alex F. Herrera, MD

137 Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera
Session: 904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients
Program: Oral and Poster Abstracts
Type: Oral
Time: 10:30 AM
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

Andrew T. Kuykendall, MD, Abdulraheem Yacoub, MD, Nancy Reaven, Susan Funk, Pedro Oyuela, MD, Frank Valone, MD, Phil Dinh, Lucy Bellamy, Nikita Modi, PharmD, Arturo Molina, MD, MS, FACP and Suneel Gupta, PhD

355 Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Oral
Time: 4 PM
Location: Room 6B (San Diego Convention Center)

Roni Shouval, MD, PhD, Christopher Strouse, MD, Soyoung Kim, PhD, Temitope Oloyede, MPH, Sairah Ahmed, MD, Farrukh T. Awan, MD, Veronika Bachanova, MD, PhD, Talha Badar, MD, Pere Barba, MD, Amer M. Beitinjaneh, MD, MS, Amanda F Cashen, Bhagirathbhai Dholaria, MBBS, Mahmoud Elsawy, MD, MSc, Siddhartha Ganguly, MD, Praveen Ramakrishnan Geethakumari, MD, MS, Uri Greenbaum, MD, Hamza Hashmi, MD, Laquisa C. Hill, BS, MD, Michael D. Jain, MD, PhD, Tania Jain, MD, Partow Kebriaei, MD, Adam S Kittai, MD, Frederick L. Locke, MD, Premal D. Lulla, MBBS, Elena Mead, MD, Joseph P McGuirk, DO, Alberto Mussetti, Taiga Nishihori, MD, Amanda L. Olson, MD, Martina Pennisi, Miguel-Angel Perales, MD, Peter A. Riedell, MD, Wael Saber, MD, MS, Sayeef Mirza, MD, MPH, Margarida Magalhaes-Silverman, MD, Elizabeth J. Shpall, MD, Mohamed Sorror, MD, MSc, Kitsada Wudhikarn, MD, Cameron J. Turtle, MBBS, PhD, Marcelo Pasquini, MD, MS and Amy Moskop, MD

1535 A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Uma M. Borate, MBBS, MS, Ying Huang, MS, MA, Mary F. Johnson, PhD, Joshua F. Zeidner, MD, Ronan T. Swords, MD, PhD, FRCP, FRCPath, Kristin L Koenig, MD, Eytan M. Stein, Maria R. Baer, MD, Wendy Stock, MD, Yazan F. Madanat, MD, Rebecca Olin, MD MSCE, William Blum, MD, Gary J. Schiller, MD, Tara L Lin, MD, Robert L. Redner, MD, Emily K Curran, MD, Nyla A. Heerema, PhD, Molly Martycz, Leonard Rosenberg, Sonja Gullen Marcus, MPH, Timothy Chen, PhD, Mona Stefanos, MD, Ross L Levine, MD, Brian J. Druker, MD, Ashley Owen Yocum, PhD, Amy Burd, PhD, Alice Mims, MD and John C. Byrd, MD

2159 ¹³¹I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Stuart Seropian, MD, James M. Foran, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, Hannah Choe, MD, Mark R. Litzow, MD, Nebu Koshy, MD, Patrick J. Stiff, MD, Ben K. Tomlinson, MD, Sunil Abhyankar, MD, Sameem Abedin, MD, George Chen, MD, Zaid Al-Kadhimi, MD, Partow Kebriaei, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes-Silverman, MD, Koen Van Besien, MD, PhD, Michael W. Schuster, MD, Arjun D. Law, MD, Sebastian A. Mayer, MD, Hillard M. Lazarus, MD, Jennifer Spross, Kate L Li, PhD, Elaina Haeuber, MS, Madhuri Vusirikala, Akash Nahar, MD, MPH, Brenda M. Sandmaier, MD, John Pagel, MD, PhD, Sergio A. Giralt, MD, FACP, Avinash Desai, M.D and Camille N. Abboud, MD

2433 Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Session: 906. Outcomes Research – Myeloid Malignancies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Stuart Seropian, MD, James M. Foran, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, Hannah Choe, MD, Mark R. Litzow, MD, Nebu Koshy, MD, Patrick J. Stiff, MD, Ben K. Tomlinson, MD, Sunil Abhyankar, MD, Sameem Abedin, MD, George Chen, MD, Zaid Al-Kadhimi, MD, Partow Kebriaei, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes-Silverman, MD, Koen Van Besien, MD, PhD, Michael W. Schuster, MD, Arjun D. Law, MD, Sebastian A. Mayer, MD, Hillard M. Lazarus, MD, Jennifer Spross, Kate L Li, PhD, Elaina Haeuber, MS, Madhuri Vusirikala, Akash Nahar, MD, MPH, Brenda M. Sandmaier, MD, John Pagel, MD, PhD, Sergio A. Giralt, MD, FACP, Avinash Desai, M.D and Camille N. Abboud, MD

2121 Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Swetha Kambhampati, MD, Hai-Lin Wang, MPH, Jiali Yan, MS, Alex F. Herrera, MD, Matthew J. Frank, MD, PhD, Leslie L. Popplewell, MD, FACP, MPH, Nausheen Ahmed, MD, Yi Lin, MD, PhD, Frederick L. Locke, MD, Paola Ghione, MD, MSEpi, John G. Gribben, MD, DSc, Timothy Best, Christine Fu, PhD, Sara Beygi, MD, Markqayne D Ray, PharmD, John Bian, PhD, Zhen-Huan Hu, MPH, Fang Sun, MD, PhD, Marcelo Pasquini, MD, MS and Caron A Jacobson, MD, MMSc

1969 Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Who Received at Least 2 BCMA-Directed Therapies

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Jordan Snyder, PharmD, Zain Alsaddi, Omar Alkharabsheh, MBBS, Barry Paul, Forat Lutfi, MD, Nausheen Ahmed, MD, Zahra Mahmoudjafari, PharmD, Al-Ola Abdallah, MD and Shebli Atrash, MD

1971 Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Priyanka Venkatesh, MBBS, Ghena Khasawneh, MD, Hamza Hashmi, MD, Omar Alkharabsheh, MD, Barry Paul, Barry S. Skikne, MD, Zahra Mahmoudjafari, PharmD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Shebli Atrash, MD

1985 Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics, Clinically Relevant Abstract

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Jordan Snyder, PharmD, Razan Mansour, Aytaj Mammadzadeh, Hamza Hashmi, MD, Aimaz Afrough, MD, Omar Alkharabsheh, MBBS, Barry Paul, Shebli Atrash, MD, Muhammad Umair Mushtaq, MD, Barry S. Skikne, MD, Nausheen Ahmed, MD and Al-Ola Abdallah, MD

2344 The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Session: 902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Aroog Khaliq, William Wesson, MPH, Emerson Logan, Carine Tabak, Aliya Rashid, DO, MPH, Razan Mansour, Muhammad Umair Mushtaq, MD, Joseph P McGuirk, DO, Hamza Hashmi, MD, Mehdi Hamadani, MD, Al-Ola Abdallah, MD and Nausheen Ahmed, MD

1614 Single-Cell RNA Sequencing Facilitates Study of Cancer Mechanisms across Pediatric Leukemias

Session: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Irina Pushel, PhD, Byunggil Yoo, MS, Daniel Louiselle, MS, Margaret Gibson, MB(ASCP), Alan S Gamis, MD, MPH, Keith J. August, MD, MS, Terrie Flatt, DO, MA, Tomi Pastinen, MD, PhD, Erin M. Guest, MD and Midhat S Farooqi, MD, PhD

2242 Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Muhammad Kashif Amin, MD, Moazzam Shahzad, MD, Joe S. Al-Ramahi, Shaun DeJarnette, Forat Lutfi, MD, Nausheen Ahmed, MD, Haitham Abdelhakim, MD, Rajat Bansal, MD, Leyla Shune, MD, Al-Ola Abdallah, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Joseph P McGuirk, DO and Muhammad Umair Mushtaq, MD

1558 Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Nam Nguyen, MS, PharmD, Phani Krishna Parcha, PhD, Abderrahmane Tagmount, PhD, Bailey Gregory, Jeffrey E. Rubnitz, MD, PhD, Raul C. Ribeiro, MD, Xueyuan Cao, PhD, Todd A. Alonzo, PhD, Richard Aplenc, MD, PhD, Alan S Gamis, MD, MPH, Todd Cooper, DO, E. Anders Kolb, MD, Soheil Meshinchi, MD, PhD, Stanley Pounds, PhD, Christopher Vulpe, MD, PhD and Jatinder K. Lamba, PhD

981 Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Krish Patel, MD, Julie M. Vose, MD, MBA, Sunita D. Nasta, MD, FACP, Jennifer R. Brown, MD, PhD, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Nirav N. Shah, MD, Bita Fakhri, MD, MPH, Benoit Tessoulin, Shuo Ma, MD, PhD, Deepa Jagadeesh, MD, Ewa Lech-Maranda, MD, PhD, Catherine C. Coombs, MD, Manish Patel, MD, Joanna M. Rhodes, MD, Chaitra S Ujjani, MD, Marc Hoffmann, MD, Chan Y Cheah, MBBS, FRACP, FRCPA, DMSc, Talha Munir, MBBS, MRCP, FRCPath, PhD, David Lewis, MBChB, PHD, Lydia Scarfo, MD, Toby A. Eyre, Alvaro J. Alencar, MD, Jonathon B. Cohen, MD, MS, Andrew D. Zelenetz, MD, PhD, Donald E. Tsai, MD, PhD, Mei Li, MS, Faith Bian, PhD, Paolo Abada, MD and Pier Luigi Zinzani, MD, PhD

1737 Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study, Clinically Relevant Abstract

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

William G. Wierda, MD, PhD, Nirav N. Shah, MD, Chan Yoon Cheah, MD, David Lewis, MBChB, PHD, Marc Hoffmann, MD, Catherine C. Coombs, MD, Nicole Lamanna, MD, Shuo Ma, MD, PhD, Deepa Jagadeesh, MD, Talha Munir, MBBS, MRCP, FRCPath, PhD, Yucai Wang, MD, PhD, Toby A. Eyre, Joanna M. Rhodes, MD, Matthew McKinney, MD, Ewa Lech-Maranda, MD, PhD, Constantine S. Tam, MD, MBBS, Wojciech Jurczak, MD, PhD, Koji Izutsu, MD, PhD, Alvaro J. Alencar, MD, Manish Patel, MD, John F. Seymour, MBBS, PhD, FRACP, Jennifer A. Woyach, MD, Lindsey E. Roeker, MD, Philip A. Thompson, MBBS, Paolo Abada, MD, Caleb Ho, M.D., Narasimha Marella, Ph.D., Chunxiao Wang, Ph.D., Amy S. Ruppert, PhD, Binoj Chandrasekharan Nair, Ph.D., Hui Liu, Ph.D., Donald E. Tsai, MD, PhD and Paolo Ghia, MD, PhD

2122 Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Chiranjeevi Sainatham, MBBS, Olga Goloubeva, Philip Margiotta, MD, Hanan Alharthy, MBBS4, Imari Patel, Ali Bukhari, MD, MS, Jennie Law, MD, Seung Tae Lee, MD, Mehmet H. Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Maggie Nelson, PharmD, Joseph P McGuirk, DO, Aaron P. Rapoport, MD, Saurabh Dahiya and Forat Lutfi, MD

2133 Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

Kevin O. McNerney, MD, MSc, Vanessa A. Fabrizio, MD, Aimee C. Talleur, MD, Stephanie Si Lim, MD, Alexandra Dreyzin, MD, Christina Baggott, PhD, Anant Vatsayan, MBBS, Jenna Rossoff, MD, Snehit Prabhu, PhD, Holly L. Pacenta, MD, Christine L Phillips, MD, Julie-An Talano, MD, Amy Moskop, MD, Michael R Verneris, MD, Douglas Myers, MD, Nicole Karras, MD, Challice L. Bonifant, MD, PhD, Muna Qayed, MD, Michelle L. Hermiston, MD, PhD, Prakash Satwani, MD, MBBS, Christa Krupski, DO, MPH, Amy Keating, MD, Susanne H.C. Baumeister, MD, Vasant Chinnabhandar, MD, MBBS, Emily Egeler, Kevin J Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD, Liora Michal Schultz, MD and Swati Naik, MBBS

2136 Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 5:30 PM
Location: Halls G-H (San Diego Convention Center)

William Wesson, MPH, Nausheen Ahmed, MD, James A Davis, PharmD, Mary McGann, PharmD, Aliya Rashid, DO, MPH, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, MBI, Maggie Nelson, PharmD, Leyla Shune, MD, Marc Hoffmann, MD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

December 10, 2023

469 ¹³¹I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies
Program: Oral and Poster Abstracts
Type: Oral
Time: 9:30 AM
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

Hannah Choe, MD, Ben K. Tomlinson, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, Stuart Seropian, MD, Mark R. Litzow, MD, Camille N. Abboud, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, James M. Foran, MD, Sameem Abedin, MD, George Chen, MD, Zaid Al-Kadhimi, MD, Partow Kebriaei, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes-Silverman, MD, Koen Van Besien, MD, PhD, Michael W. Schuster, MD, Arjun D. Law, MD, Sebastian A. Mayer, MD, Hillard M. Lazarus, MD, Jennifer Spross, Kate L Li, PhD, Elaina Haeuber, MS, Madhuri Vusirikala, Akash Nahar, MD, MPH, Brenda M. Sandmaier, MD, John Pagel, MD, PhD, Sergio A. Giralt, MD, FACP, Avinash Desai, M.D and Nebu Koshy, MD

469 ¹³¹I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification
Program: Oral and Poster Abstracts
Type: Oral
Time: 4:30 PM
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

Hannah Choe, MD, Ben K. Tomlinson, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, Stuart Seropian, MD, Mark R. Litzow, MD, Camille N. Abboud, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, James M. Foran, MD, Sameem Abedin, MD, George Chen, MD, Zaid Al-Kadhimi, MD, Partow Kebriaei, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes-Silverman, MD, Koen Van Besien, MD, PhD, Michael W. Schuster, MD, Arjun D. Law, MD, Sebastian A. Mayer, MD, Hillard M. Lazarus, MD, Jennifer Spross, Kate L Li, PhD, Elaina Haeuber, MS, Madhuri Vusirikala, Akash Nahar, MD, MPH, Brenda M. Sandmaier, MD, John Pagel, MD, PhD, Sergio A. Giralt, MD, FACP, Avinash Desai, M.D and Nebu Koshy, MD

655 Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group, Clinically Relevant Abstract

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Program: Oral and Poster Abstracts
Type: Poster
Time: 4:30 PM
Location: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)

Benjamin J Huang, MD, Lauren K. Meyer, MD, PhD, Adam Lamble, MD, Jim Wang, MS, Rhonda E Ries, MA, Alan S Gamis, MD, MPH, Richard Aplenc, MD, PhD, Katherine Tarlock, MD, Todd Cooper, DO, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD, Joseph Chewning, MD, William G. Woods, MD and John T. Horan, MD

601 Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up, Clinically Relevant Abstract

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy 
Program: Oral and Poster Abstracts
Type: Oral
Time: 4:30 PM
Location: Grand Hall C (Manchester Grand Hyatt San Diego)

Stephen J Schuster, MD, Nathan Fowler, MD, Michael Dickinson, MBBS, D. Med Sci, FRACP, FRCPA, Joaquin Martinez-Lopez, MD, PhD, Arne Kolstad, MD, PhD, Jason Butler, MBBS, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, MPH, Julio C Chavez, MD, Emmanuel Bachy, MD, PhD, Koji Kato, M.D., Ph.D., Hideo Harigae, Marie José Kersten, MD, PhD, Charalambos Andreadis, Peter A Riedell, Phoebe Joy Ho, MBBS, FRACP, FRCPA, Jose A. Perez-Simon, MD, PhD, Andy Chen, MD, PhD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andrés José María Ferreri, MD, Takanori Teshima, Piers Patten, FRCP, FRCPath, PhD, Joseph P McGuirk, DO, Andreas L Petzer, MD, Fritz Offner, MD, Andreas Viardot, MD PhD, Pier Luigi Zinzani, MD, PhD, Ram Malladi, PhD, Aiesha Zia, Rakesh Awasthi, PhD, Ines Paule, Davide Germano, Roberto Javier Ramos, MD, Pei Hsu, Catherine Thieblemont, MD and Martin Dreyling, MD

617 Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas 
Program: Oral and Poster Abstracts
Type: Oral
Time: 5:30 PM
Location: Ballroom 20AB (San Diego Convention Center)

Peter A Riedell, MD, Connor Grady, MPH, Loretta J. Nastoupil, MD, Alejandro Luna, MD, PhD, Nausheen Ahmed, MD, Richard T Maziarz, MD, Marie Hu, MD, Jamie Brower, MS, Wei-Ting Hwang, PhD, Stephen J Schuster, MD, Andy Chen, MD, PhD, Olalekan O. Oluwole, MBBS, Veronika Bachanova, MD, PhD, Joseph P McGuirk, DO, Miguel-Angel Perales, MD, Michael R. Bishop, MD and David L. Porter, MD

617 Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Rawan Atallah, Yara Shatnawi, MD, Aytaj Mammadzadeh, Shahrukh K Hashmi, MD, MPH, Shabeeha K Rana, MBBS, MRCP, FRCPath, Muhammad Umair Mushtaq, MD, Benlazar Mohamed, MD, Nihar Desai, MBBS, Thiago Xavier Carneiro, MD, Rakesh Popat, Joseph P McGuirk, DO, Shebli Atrash, MD, Zahra Mahmoudjafari, PharmD, Al-Ola Abdallah, MD and Nausheen Ahmed, MD

3330 Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Danai Dima, MD, Aishwarya Sannareddy, MBBS, Nausheen Ahmed, MD, James A Davis, PharmD, Hira Shaikh, MBBS, Zahra Mahmoudjafari, PharmD, Marissa Duco, PharmD, Jack Khouri, MD, Gurbakhash Kaur, MD, MA, Jonathan Lochner, PharmD, Faiz Anwer, MD, Aimaz Afrough, MD, Jason Valent, MD, Hamza Hashmi, MD and Al-Ola Abdallah, MD

3361 Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Razan Mansour, James A Davis, PharmD, Megan Minchak, Rawan Atallah, Md Saiful Islam Saif, Emerson Logan, Carine Tabak, Aliya Rashid, DO, MPH, Danai Dima, MD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

3499 Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Shonali Midha, MD, BS, Ashwath Gurumurthi, MBBS, Patrick Costello, Robert A. Redd, MS, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP, Omar Castaneda, MD, Rebecca Gonzalez, PharmD, Filip Ionescu, MD, Mahmoud Gaballa, MD, Nilesh Kalariya, PhD, RN, Jack Khouri, MD, Danai Dima, MD, Mehmet H. Kocoglu, MD, Douglas Sborov, MD, MS, Charlotte B Wagner, PharmD, Shebli Atrash, MD, Peter M. Voorhees, MD, Hamza Hashmi, MD, James A Davis, PharmD, Peter A. Forsberg, MD, Joseph P McGuirk, DO, Leyla Shune, MD, Megan Herr, PhD, Ran Reshef, MD, MSc, Yi Lin, MD, PhD, Myo Htut, MD, Thomas Martin, MD, Surbhi Sidana, MD, Doris K. Hansen, MD, Omar Nadeem, MD and Krina K. Patel, MD, MSc

3503 Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

James A Davis, PharmD, Danai Dima, MD, Nausheen Ahmed, MD, Shaun DeJarnette, Joseph P McGuirk, DO, Jack Khouri, MD, Jason Valent, MD, Faiz Anwer, MD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

3523 Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation, Clinically Relevant Abstract

Session: 711. Cell Collection and Processing: Poster II Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Moazzam Shahzad, MD, Joe S. Al-Ramahi, Muhammad Kashif Amin, MD, Muhammad Fareed Khalid, MD, Shaun DeJarnette, Zahra Mahmoudjafari, PharmD, Maggie Nelson, PharmD, Riley Hastings, Haitham Abdelhakim, MD, Forat Lutfi, MD, Nausheen Ahmed, MD, Rajat Bansal, MD, Leyla Shune, MD, Al-Ola Abdallah, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Joseph P McGuirk, DO and Muhammad Umair Mushtaq, MD

2700 Spatial Transcriptomics Reveals Distinct Hematopoietic Stem Cell Niches in Mouse Fetal Liver

Session: 506. Bone Marrow Microenvironment: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Ruochen Dong, PhD, BM, Hua Li, Xi He, MD, Anoja Perera, Seth Malloy, Jonathon Russell, Wenting Li, Kaitlyn Petentler, Xinjian Mao, PhD, Zhe Yang, Michael Epp, Kate Hall, Allison Scott, Sarah Smith, Mark Hembree, Yongfu Wang, Sean McKinney, Jeff Haug, Jay Unruh, Brian Slaughter and Linheng Li, PhD

3187 Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Julian Waksal, MD, Ronald Hoffman, MD, Abdulraheem Yacoub, MD, Francesco Passamonti, MD, Aaron T. Gerds, MD, MS, Vikas Gupta, MD, Grace Van Hyfte, Jayanshu Jain, MD, Margherita Maffioli, Natalia Rosas and John Mascarenhas, MD

2926 Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Satyavardhan Rao Nittu, PharmD, Francisco Marchi, Nam Nguyen, MS, PharmD, Vivek M. Shastri, PhD, Xueyuan Cao, PhD, Raul C. Ribeiro, MD, Jeffrey E. Rubnitz, MD, PhD, Alan S Gamis, MD, MPH, E. Anders Kolb, MD, Richard Aplenc, MD, PhD, Jeffery Klco, MD, PhD, Stanley Pounds, PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, PhD

2956 Integrated Methylation and Transcriptional Landscape and Evolution of Pediatric AML

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Benjamin J Huang, MD, Hamid Bolouri, PhD, Colin Y. Smith, Jim Wang, MS, Rhonda E Ries, MA, Elizabeth Conran, Alan S Gamis, MD, MPH, Richard Aplenc, MD, PhD, Todd A. Alonzo, PhD, Xiaotu Ma, PhD, Timothy Junius Triche, PhD, Jason E. Farrar, MD and Soheil Meshinchi, MD, PhD

2983 Trajectory Inference Highlights Dynamic Expression of T-Cell Development Genes in Pediatric T-Cell Acute Lymphoblastic Leukemia

Session: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Irina Pushel, PhD, Byunggil Yoo, MS, Daniel Louiselle, MS, Margaret Gibson, MB(ASCP), Erin M. Guest, MD, Midhat S Farooqi, MD, PhD and Keith J. August, MD, MS

3391 Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Jesus G. Berdeja, MD, David Dingli, MD, Sagar Lonial, MD, Andrew J. Yee, MD, Alfred Chung, MD, Cristina Gasparetto, MD, P. Leif Bergsagel, MD, Vivek Roy, MD, Al-Ola Abdallah, MD, Sharmilan Thanendrarajan, MD, Aimaz Afrough, MD, Laura Rosiñol, MD, PhD, Suzanne Trudel, MD, FRCPC, Paula Rodriguez Otero, MD, PhD, Cyrille Touzeau, MD, PhD, Pierre Bories, MD, PhD, Soo Bang, MHSA, Terry Connolly, PhD, Michelle Kim, Chad A. Lewis, PhD, Bao-Van Tran Linberg, M. Travis Quigley, Ola Landgren, MD, Saad Z Usmani, MD, Maria-Victoria Mateos and David S. Siegel, MD, PhD

3088 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Gulrayz Ahmed, MD, FACP, Aseel Alsouqi, MD, Aniko Szabo, PhD, Alexandra E. Rojek, MD, Peter A. Riedell, MD, Farrukh T. Awan, MD, Laura Samples, MD, Mazyar Shadman, MD, MPH, Marie Hu, MD, Veronika Bachanova, MD, PhD, William Wesson, MPH, Nausheen Ahmed, MD, Madiha Iqbal, MD11, Mohamed A. Kharfan-Dabaja, MD, MBA12, Michael Scordo13, Patrick Connor Johnson, MD, Yi-Bin Chen, MD, MS, Sawa Ito, MD, Mehdi Hamadani, MD and Matthew J. Frigault, MD, MS

2877 Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Session: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Selina M Luger, MD, FRCPC, Zhuoxin Sun, PhD, Ryan J Mattison, MD, Elisabeth Paietta, PhD, Kathryn G. Roberts, PhD, Yanming Zhang, M.D., Janis Racevckis, Hillard M. Lazarus, MD, Jacob M. Rowe, MB, BS, Daniel A. Arber, MD, Matthew J. Wieduwilt, MD, Michaela Liedtke, MD, Julie Bergeron, MD, Brent L. Wood, MD, PhD, Yaqi Zhao, MSc, Gang Wu, PhD, Ti-Cheng Chang, Wenchao Zhang, Keith W Pratz, MD, Shira N. Dinner, MD, Noelle V. Frey, MD, MS, Steven D. Gore, MD, Bhavana Bhatnagar, DO, Ehab L. Atallah, MD, Geoffrey L Uy, MD, Deepa Jeyakumar, MD, Tara L Lin, MD, Cheryl L. Willman, MD, Daniel J. DeAngelo, Elad Sharon, MD, MPH, Richard F. Little, MD, MPH, Harry P. Erba, MD, PhD, Richard M Stone, MD, Charles G. Mullighan, MBBS, MD, Mark R. Litzow, MD and Martin S. Tallman, MD

3529 High-Dose Targeted Radiation with ¹³¹I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Mark R. Litzow, MD, George Chen, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, Stuart Seropian, MD, Hannah Choe, MD, Camille N. Abboud, MD, Nebu Koshy, MD, Ben K. Tomlinson, MD, Sunil Abhyankar, MD, James M. Foran, MD, Sameem Abedin, MD, Zaid Al-Kadhimi, MD, Partow Kebriaei, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes-Silverman, MD, Koen Van Besien, MD, PhD, Michael W. Schuster, MD, Arjun D. Law, MD, Sebastian A. Mayer, MD, Hillard M. Lazarus, MD, Eugene Leung, MD, FRCPC, Ming-Kai Chen, MD, PhD, Mona Natwa, MD, Jennifer Spross, Kate L Li, PhD, Norman Nagl, PhD, Elaina Haeuber, MS, Madhuri Vusirikala, Akash Nahar, MD, MPH, Brenda M. Sandmaier, MD, John Pagel, MD, PhD, Sergio A. Giralt, MD, FACP, Avinash Desai, M.D, Richard L. Wahl, MD, Neeta Pandit-Taskar, MD, Patrik Brodin and Patrick J. Stiff, MD 

December 11, 2023

835 A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features
Program: Oral and Poster Abstracts
Type: Oral
Time: 2:45 PM
Location: Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, PhD, Raul C. Ribeiro, MD, Jeffrey E. Rubnitz, MD, PhD, Alan S Gamis, MD, MPH, E. Anders Kolb, MD, Richard Aplenc, MD, PhD, Stanley Pounds, PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, PhD

1027 Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real-World Evidence
Program: Oral and Poster Abstracts
Type: Oral
Time: 4:30 PM
Location: Room 6CF (San Diego Convention Center)

Surbhi Sidana, MD, Nausheen Ahmed, MD, Othman S Akhtar, MD, Michael Heim, MS, Ruta Brazauskas, PhD, Doris K. Hansen, MD, Christopher Ferreri, MD, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP, Aimaz Afrough, MD, Larry D. Anderson Jr., MD, PhD, Binod Dhakal, MD, MS, Devender Dhanda, PhD, Lohith Gowda, MD, Hamza Hashmi, MD, Melanie Harrison, Amani Kitali, MBA, MPH, PMP, Sayeef Mirza, MD, MPH, Jinalben Patel, MPH, Pallavi Patwardhan, Saad Z Usmani, MD, Krina K. Patel, MD, MSc, Siddhartha Ganguly, MD and Marcelo Pasquini, MD, MS

973 Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated Clinically Relevant Abstract

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant
Program: Oral and Poster Abstracts
Type: Oral
Time: 4:30 PM
Location: Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

Mark J. Levis, MD, PhD, Mehdi Hamadani, MD, Brent R. Logan, PhD, Richard J. Jones, MD, Anurag K. Singh, MD, Mark R. Litzow, MD, John R. Wingard, MD, Esperanza B. Papadopoulos, MD, Alexander Perl, Robert J. Soiffer, MD, Celalettin Ustun, MD, Masumi Ueda Oshima, MD, Geoffrey L Uy, MD, Edmund K. Waller, MD, Sumithira Vasu, MD, MBBS, Melhem M. Solh, MD, Asmita Mishra, MD, MBA, Lori S. Muffly, MD, Hee-Je Kim, Matthias Stelljes, MD, Yuho Najima, MD, PhD, Masahiro Onozawa, M.D., Ph.D., Kirsty Thomson, MB ChB, Arnon Nagler, MD, M.Sc, Andrew H. Wei, MBBS, PhD, Guido Marcucci, MD, Nahla Hasabou, MD, Mathew Rosales, PhD, Jason Hill, PhD, Stanley C. Gill, PhD, Rishita Nuthethi, PhD, Denise King, MS, CCRA, Heather Wittsack, MPH, Adam Mendizabel, PhD, Steven M. Devine, MD, Mary M. Horowitz, MD and Yi-Bin Chen, MD, MS

981 Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Oral
Time: 5 PM
Location: Room 6CF (San Diego Convention Center)

Jonathon B. Cohen, MD, MS, Nirav N. Shah, MD, Wojciech Jurczak, MD, PhD, Pier Luigi Zinzani, MD, PhD, Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc, Toby A. Eyre, Chaitra S Ujjani, MD, Youngil Koh, MD, Won Seog Kim, MD, MPH, PhD, Sunita D. Nasta, MD, FACP, Ian W. Flinn, MD, PhD, Benoit Tessoulin, Shuo Ma, MD, PhD, Alvaro J. Alencar, MD, David Lewis, MBChB, PHD, Jennifer A. Woyach, MD, Kami J. Maddocks, MD, Krish Patel, MD, Yucai Wang, MD, PhD, Joanna M. Rhodes, MD, MSCE, Constantine S. Tam, MD, MBBS, John F. Seymour, MBBS, PhD, FRACP, Hirokazu Nagai, MD, PhD, Julie M. Vose, MD, MBA, Bita Fakhri, MD, MPH, Marc Hoffmann, MD, Francisco J. Hernandez-Ilizaliturri, MD, Andrew D. Zelenetz, MD, PhD, Anita Kumar, MD, Talha Munir, MBBS, MRCP, FRCPath, PhD, Donald E. Tsai, MD, PhD, Minna Balbas, PhD, Bin Liu, MSc, MPH, Amy S. Ruppert, PhD, Bastien Nguyen, PhD, Lindsey E. Roeker, MD and Michael L. Wang, MD

1012 Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Oral
Time: 5:15 PM
Location: Room 6CF (San Diego Convention Center)

Sumit Madan, MD, Caitlin L. Costello, MD, Brea Lipe, MD, Andrew J. Cowan, MD, Eva Medvedova, MD, Jens Hillengass, MD, PhD, P. Leif Bergsagel, MD, Xavier Leleu, MD, Cyrille Touzeau, MD, PhD, Daniel Morillo, MD, Albert Oriol, Raya Mawad, MD, Henning Schade, MD, Salomon Manier, MD, PhD, Yifah Yaron, MD, PhD, Banmeet Anand, PhD and Al-Ola Abdallah, MD

1032 Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real-World Evidence
Program: Oral and Poster Abstracts
Type: Oral
Time: 5:45 PM
Location: Room 6CF (San Diego Convention Center)

Jay Y. Spiegel, MD, FRCPC, Michael D. Jain, MD, PhD, Loretta J. Nastoupil, MD, John Tamaresis, PhD, Armin Ghobadi, MD, Yi Lin, MD, PhD, Lazaros J. Lekakis, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, Joseph P McGuirk, DO, Abhinav Deol, MD, Kathleen Dorritie, MD, Alison R Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Charalambos Andreadis, MD, Javier L. Munoz, Matthew L. Ulrickson, MD, Jason Westin, MD, Julio C. Chavez, MD, Dilan A Patel, Miriam T. Jacobs, MD, Radhika Bansal, MBBS, N. Nora Bennani, MD, Vivek Patel, MD, Aaron P. Rapoport, MD, Julie M. Vose, MD, MBA, David B. Miklos, MD, PhD, Sattva S. Neelapu, MD, Frederick L. Locke, MD, Matthew A. Lunning, DO, FACP and Saurabh Dahiya

4876 Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Saurabh Dahiya, Jay Y. Spiegel, MD, FRCPC, Dasom Lee, MD, Turab Mohammed, MD, Forat Lutfi, MD, Anmol Goyal, MD, Caroline Hana, Julio C Chavez, MD, Filip Ionescu, MD, Matthew J. Frank, MD, PhD, Sushma Bharadwaj, MD, MS, Jose Sandoval-Sus, MD, Amer M. Beitinjaneh, MD, MS, Lazaros J. Lekakis, Joseph P McGuirk, DO, Frederick L. Locke, MD, David B. Miklos, MD, PhD and Michael D. Jain, MD, PhD

4880 Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Charlotte B Wagner, PharmD, Karen Sweiss, PharmD2, Eric Anto, M.S., Rebecca Gonzalez, PharmD, Omar Alexis Castaneda Puglianini, MD, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP, Filip Ionescu, MD, Krina K. Patel, MD, MSc, Christopher Ferreri, MD, Mahmoud Gaballa, MD, Leyla Shune, MD, Joseph P McGuirk, DO, Surbhi Sidana, MD, Vanna Hovanky, MS, Jack Khouri, MD, Danai Dima, MD, Hamza Hashmi, MD, James A Davis, PharmD, Aimaz Afrough, MD, Gurbakhash Kaur, MD, MA, Larry D. Anderson Jr., MD, PhD, Peter A. Forsberg, MD, Megan Herr, PhD, Doris K. Hansen, MD, Douglas Sborov, MD, MS and Mehmet H. Kocoglu, MD

4882 Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Danai Dima, MD, James A Davis, PharmD, Aliya Rashid, DO, MPH, Mikhaila Rice, PharmD, Shaun DeJarnette, Leyla Shune, MD, Jack Khouri, MD, Shahzad Raza, MD, Joseph P McGuirk, DO, Faiz Anwer, MD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

4885 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Danai Dima, MD, Aliya Rashid, DO, MPH, James A Davis, PharmD, Hussein Awada, Al-Ola Abdallah, MD, Hong Li, MS, Shaun DeJarnette, Leyla Shune, MD, Jack Khouri, MD, Hamza Hashmi, MD, Joseph P McGuirk, DO, Faiz Anwer, MD and Nausheen Ahmed, MD

4887 Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucelâ

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

William Wesson, MPH, Forat Lutfi, MD, David L. Porter, MD, Veronika Bachanova, MD, PhD, Loretta J. Nastoupil, MD, Peter A. Riedell, MD, Miguel-Angel Perales, MD, Richard T Maziarz, MD, Jamie Brower, MS, Gunjan L. Shah, Andy Chen, MD, PhD, Olalekan O. Oluwole, MBBS, Stephen J Schuster, MD, Michael R. Bishop, MD, Joseph P McGuirk, DO and Nausheen Ahmed, MD

4296 Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Fieke W Hoff, MD, PhD, Ying Huang, MS, MA, Rina Li Welkie, MPH, Ronan T. Swords, MD, PhD, FRCP, FRCPath, Elie Traer, Eytan M. Stein, Tara L Lin, MD, Prapti A. Patel, MD, Robert H. Collins, MD, Maria R. Baer, MD, Vu H. Duong, MD, MS, William Blum, MD, Martha Arellano, Wendy Stock, MD, Olatoyosi Odenike, Robert L. Redner, MD, Tibor J. Kovacsovics, MD, Michael W. Deininger, MD, PhD, Joshua F. Zeidner, MD, Rebecca Olin, MD MSCE, Catherine C. Smith, MD, James M. Foran, MD, Gary J. Schiller, MD, Emily K Curran, MD, Kristin L Koenig, MD, Nyla A. Heerema, PhD, Timothy Chen, PhD, Molly Martycz, Mona Stefanos, MD, Sonja Gullen Marcus, MPH, Leonard Rosenberg, Brian J. Druker, MD, Ross L Levine, MD, Amy Burd, PhD, Ashley Owen Yocum, PhD, Uma M. Borate, MBBS, MS, Alice Mims, MD, John C. Byrd, MD and Yazan F. Madanat, MD

4306 DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Rhonda E Ries, MA, Xiaotu Ma, PhD, Claudia Tregnago, PhD, Todd A. Alonzo, PhD, Jim Wang, MS, Tiffany Hylkema, BS, Benjamin J Huang, MD, Alireza Torabi, MD, PhD, Jack H Peplinski, BS, Logan K Wallace, Richard Aplenc, MD, PhD, Alan S Gamis, MD, MPH, Katherine Tarlock, MD, Franco Locatelli, MD, PhD, Martina Pigazzi, PhD and Soheil Meshinchi, MD, PhD

4314 ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Richard J Marrero, PharmD, Vivek M. Shastri, PhD, Richard Aplenc, MD, PhD, Todd Cooper, DO, Todd A. Alonzo, PhD, Alan S Gamis, MD, MPH, Jim Wang, MS, Soheil Meshinchi, MD, PhD, E. Anders Kolb, MD and Jatinder K. Lamba, PhD

4332 Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial, Clinically Relevant Abstract

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Uma M. Borate, MBBS, MS, Ying Huang, MS, MA, Rina Li Welkie, MPH, Ronan T. Swords, MD, PhD, FRCP, FRCPath, Elie Traer5, Eytan M. Stein, Tara L Lin, MD, Yazan F. Madanat, MD, Prapti A. Patel, MD, Robert H. Collins, MD, Maria R. Baer, MD, Vu H. Duong, MD, MS, William Blum, MD, Martha Arellano, Wendy Stock, MD, Olatoyosi Odenike, Robert L. Redner, MD, Tibor J. Kovacsovics, MD, Michael W. Deininger, MD, PhD, Joshua F. Zeidner, MD, Rebecca Olin, MD MSCE, Catherine C. Smith, MD, James M. Foran, MD, Gary J. Schiller, MD, Emily K Curran, MD, Kristin L Koenig, MD, Nyla A. Heerema, PhD, Timothy Chen, PhD, Molly Martycz, Mona Stefanos, MD, Sonja Gullen Marcus, MPH, Leonard Rosenberg, Brian J. Druker, MD, Ross L Levine, MD, Amy Burd, PhD, Ashley Owen Yocum, PhD, Alice Mims, MD and John C. Byrd, MD

4295 Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Robin Williams, MD, MS, Lane Miller, MD, MSc, Stephanie Massaro, MD, MPH, Elizabeth Krieger, MD, Melinda Pauly, MD, Catherine Nelson, DO, MS, Rebecca Johnson, MD, Jennifer J.G. Welch, MD, Deepa Bhojwani, MD, Babak Moghimi, MD, Philip Neff, MD, Terzah M. Horton, MD, PhD, Hamayun Imran, MBBS, MD, Raul C. Ribeiro, MD, Terri L. Guinipero, MD, Matthew A. Kutny, MD, Felipe Bautista, MD, Amy Johnson, MD, Karen Lewing, MD, Alan S Gamis, MD, MPH, Julienne Brackett, MD, MS, David McCall, MD, Teena Bhatla, MD, Maria Luisa Sulis, MD, Amy Tellinghuisen, MD, Jill C. Beck, MD and Soheil Meshinchi, MD, PhD

4005 Thermodynamic Effects of Antibodies on VWF73 Cleavage By ADAMTS13

Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Chan Meng, MD, Konstantine Halkidis, MD, PhD, Szumam Liu, PhD and X. Lianng Zheng, MD, PhD

4051 Characterization of Niche Cells and Signals Regulating Stepwise Embryonic Hematopoiesis Using Slide-Seq and Merfish Spatial Transcriptomics

Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Xinjian Mao, PhD, Ning Zhang, Xi He, MD, Kate Hall, Kaitlyn Petentler, Allison Scott, Seth Malloy, Jeff Haug, Hua Li, Anoja Perera, Jay Unruh, Brian Slaughter, Nancy Speck and Linheng Li, PhD

4459 Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Marc Hoffmann, MD, Javier L. Munoz, Jason Westin, MD, Theodoros Vassilakopoulos, PhD, Alejandro Martin Garcia-Sancho, MD, Antonio Rueda Dominguez, MD, Wojciech Jurczak, MD, PhD, Su-Peng Yeh, MD, Maria Bouzani, Argyrios Gkasiamis, MD, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li and Grzegorz S. Nowakowski, MD

4475 Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

N. Nora Bennani, MD, Pamela Atherton, Kimberly O Steinert, Lisa M. Rimsza, MD, Aung M. Tun, MD, Marc Hoffmann, MD, Mayur S. Narkhede, MBBS, Rakhee Vaidya, MD, Rabih Said, Geoffrey I Shapiro, MD, Brian A Costello, MD, Stephen M Ansell, MD, PhD and Grzegorz S. Nowakowski, MD

4227 Characteristics and Outcomes of Patients with DDX41-Mutated Acute Myeloid Leukemia: A Single-Center Experience

Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Jayanshu Jain, MD, Kenneth P Byrd, DO, Heather J Male, MD, Haitham Abdelhakim, MD, Jesus D Gonzalez-Lugo, MD and Tara L Lin, MD

4727 Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Clinically Relevant Abstract
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Aytaj Mammadzadeh, Yara Shatnawi, MD, Rawan Atallah, Benlazar Mohamed, MD, Nihar Desai, MBBS, Shahrukh K Hashmi, MD, MPH, Thiago Xavier Carneiro, MD, Hira Shaikh, MBBS, Christopher Strouse, MD, Rakesh Popat, Zahra Mahmoudjafari, PharmD, Muhammad Umair Mushtaq, MD, Al-Ola Abdallah, MD and Nausheen Ahmed, MD

4853 Inb-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy)

Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Joseph P McGuirk, DO, Sunil Abhyankar, MD, Trishna Goswami, MD, MBA, Halie Juarez, RN, Mariska ter Haak, Tyce Bruns, Samantha Youngblood and Lawrence S. Lamb, PhD

4921 A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Monzr M. Al Malki, MD, Melhem M. Solh, MD, Anurag K. Singh, MD, Rushang D. Patel, MD, PhD, Denis-Claude Roy, MD, Agata Drewniak, PhD, Gu Mi, PhD, Lorraine Tracey, PhD, Giovanni Abbadessa, MD, PhD and Richard E. Champlin, MD

4554 Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Pankit Vachhani, MD, Abdulraheem Yacoub, MD, Elie Traer, Lina Benajiba, Francesco Passamonti, Ashwin Kishtagari, MBBS, Mojtaba Akhtari, James McCloskey, MD, Sarah Buckley, MD, Purvi Suthar, Karisse Roman-Torres and John Mascarenhas, MD

4502 Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities – a Multicenter Retrospective Analysis

Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 PM
Location: Halls G-H (San Diego Convention Center)

Amneet K Bajwa, MD, MBA, Qiuhong Zhao, MS, Marcus Johannes Geer, MD, Agrima Mian, MD, MBBS, Chenyu Lin, MD, David Frame, PharmD, James Westholder, PharmD, Justin Tossey, PharmD, Monalisa Ghosh, MD, Ahmed Galal, MD, Nausheen Ahmed, MD, Joseph E. Maakaron, MD, Nathan Denlinger, MS, DO, Marcos de Lima, MD, Narendranath Epperla, MD, MS, Paolo F. Caimi, MD and Timothy Voorhees, MD, MSCR

December 5, 2023

Hormone replacement and alternatives for relief of vasomotor symptoms in women at increased risk for breast cancer
Session Title: Concurrent Special Session 2: Prevention, Early Detection, and Interception
Session Date/Time: Tuesday, December 5, 12 - 2 PM
Session Location: Stars at Night Ballroom 3-4 
Carol J. Fabian (presenter and moderator)

*The below content was pulled from currently available information on ASTRO's website as well as supplied by KU Cancer Center members.

October 2, 2023

Towards clinical proton minibeam radiation therapy (pMBRT): development of clinical pMBRT system prototype and pMBRT-specific treatment planning method
Scientific Session Title: SS 12 - Phys 3: FLASH and Novel Techniques
Session Date/Time: October 2, 3:30 PM - 3:37 PM
Session Location: Room 30 A/B/C
H. Gao, Y. Lin, W. Zhang, Y. Prezado, E. Traneus, D. Johnson, W. Li, G. N. Gan, and R. C. Chen

*Hao Gao, PhD has been awarded the ASTRO 2023 Basic/Translational Science Award (Senior Investigator, Physics) for this abstract. More information here. 

October 3, 2023

Hypofractionation for Regional Nodal Irradiation: Investigational Only
Scientific Session Title: EDU 18 - Hypofractionation for Regional Nodal Irradiation: Standard of Care or Investigational Only?
Session Date/Time: October 3, 8:17 AM - 8:32 AM
Session Location: Room 6B
Julia White
 
SEA-Net: Structure-Enhanced Attention Network for Limited-Angle CBCT Reconstruction of Clinical Projection Data
Scientific Session Title: QP 08 - Phys 5: Motion and Imaging
Session Date/Time: October 3, 8:20 AM - 8:25 AM
Session Location: Room 8
D. Hu, Y. Zhang, W. Li, W. Zhang, K. Reddy, Y. Chen and H. Gao
 
Proton LET optimization via iterative convex relaxation method
Scientific Session Title: QP 13 - Phys 7: FLASH and Novel Delivery
Session Date/Time: October 3, 4:20 PM - 4:25 PM
Session Location: Room 7
W. Li, Y. Lin, H. Li, R. Rotondo and H. Gao
 
Investigating the role of MK2 in Head and Neck Squamous Cell Carcinoma growth, metastasis and STING pathway activation
Scientific Session Title: Bio 7: Adaptive Immunity and Radiation 
Session Date/Time: October 3, 5:15 PM - 6:15 PM
Deri Morgan, Colby Spiess, Grace Millington, Alyssa Schmidt, Hanna Smith, Dakota Okwuone, Kiersten Berggren, Christopher Lominska, Mary Markiewicz, Tonia Yelder, Hao Gao, Jingxin Wang, Gregory Gan 
 
Medical Student Survey of ASCO Sponsored Oncology Interest Groups in the United States Demonstrates Lack of Education in Radiation Oncology and Negative Perceptions of Future Employment Prospects
Scientific Session Title: PQA 08 - Poster Q&A 08 - Gynecological Cancer, Pediatric Cancer, and Professional Development
Session Date/Time: October 3, 5:15 PM - 6:15 PM
Session Location: Hall B2
Andrew Hoover
 
Correlation of Post-Treatment Biopsy and Fluorodeoxyglucose PET/CT Findings Following Definitive Chemotherapy and Radiation for Cervical Cancer
Scientific Session Title: PQA 08 - Poster Q&A 08 - Gynecological Cancer, Pediatric Cancer, and Professional Development
Session Date/Time: October 3, 5:15 PM - 6:15 PM
Session Location: Hall B2
Andrew Hoover

October 4, 2023

EDU 39 - Microbiome to Phageome: Clinical and Biological Impact on Precision Radiation
Scientific Session Title: Bio 7: Adaptive Immunity and Radiation 
Session Date/Time: October 4, 8:00 AM - 9:00 AM
Session Location: Room 30 A/B/C
Moderators: Subhrajit Saha and Gregory Gan
 
A new treatment planning method for efficient proton ARC therapy with direct minimization of number of energy jumps.
Scientific Session Title: PQA 10 - Poster Q&A 10 - Physics
Session Date/Time: October 4, 12:30 PM - 1:45 PM
Session Location: Hall B2
G. Zhang, H. Shen, Y. Long, Y. Lin, R. C. Chen and H. Gao
 
Virtual-collimator based spatial dose modulation for proton GRID therapy. 
Scientific Session Title: PQA 10 - Poster Q&A 10 - Physics
Session Date/Time: October 4, 12:30 PM - 1:45 PM
Session Location: Hall B2
W. Zhang, E. Traneus, Y. Lin, G. N. Gan, R. C. Chen and H. Gao

Abstract / Poster Only

Sarcopenia As A Predictor For Poor Tolerance to Chemotherapy during Definitive Treatment of Primary Anal Squamous Cell Carcinoma
Andrew Hoover
 
An effective dose rate optimization algorithm for efficient conventional-dose-rate proton therapy and ultra-high-dose-rate FLASH proton therapy
Y. Zhu, X. Zhang, Y. Lin, C. Lominska and H. Gao 

Proton LET optimization via iterative convex relaxation method
W. Li, Y. Lin, H. Li, R. Rotondo and H. Gao
 
Vertex position optimization for LATTICE therapy
W. Zhang, Y. Lin, F. Wang, R. K. Badkul, R. C. Chen and H. Gao

2V-CBCT: two-orthogonal-projection based CBCT reconstruction and dose calculation from real CBCT projection data
Y. Zhang, D. Hu, W. Li, W. Zhang, R. C. Chen, Y. Chen and H. Gao

June 2, 2023

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.
2:45 – 5:45 p.m.
Hall D1, Livestream
Oral Abstract Session
Session Title: Breast Cancer – Local/Regional/Adjuvant
Track: Breast Cancer
Shane Stecklein

June 3, 2023

Nutrient Signaling and Multimodality Approaches for Cancer Cachexia
8 – 9:15 a.m.
E451, On Demand
Education Session
Session Title: Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach
Track: Symptoms and Survivorship | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Lung Cancer
Jill Hamilton-Reeves

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Track: Genitourinary Cancer—Prostate, Testicular, and Penile; Sub Track: Prostate Cancer - Advanced/Castrate-Resistant
Abstract #TPS5110; Poster Bd #198a
Chinmay Jani, Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac, Arif Hussain, Christos Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, Salma Jabbour, S. Percy Ivy, Eliezer Van Allen, Neal Lindeman, Bose Kochupurakkal, Geoffrey Shapiro, Rana McKay

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Genitourinary Cancer—Kidney and Bladder
Track: Genitourinary Cancer—Kidney and Bladder; Sub Track: Urothelial Cancer - Advanced/Metastatic Disease
Abstract #TPS4609; Poster Bd #97a
Shilpa Gupta, Karla Ballman, Matt Galsky, Michael Morris, Srikala Sridhar, Ronald Chen, Timothy Chan, Yujia Wen, Petros Grivas, Alan Tan, Shiva Baghaie, Jonathan Rosenberg

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Sarcoma
Track: Sarcoma; Sub Track: Bone Tumors
Abstract #11531; Poster Bd #465
Kristine Lacuna, Shing Lee, Liner Ge, Mihaela Druta, Anthony Conley, Mary Louise Keohan, Mark Agulnik, Melissa Burgess, Anna Chalmers, Gina D'Amato, Benjamin Powers, Mahesh Seetharam, Brittany Siontis, Mia Weiss, Sminu Bose, Tahir Sheikh, Richard Piekarz, Gary Schwartz, Matthew Ingham

Patient navigation for lung cancer screening in an urban safety-net system: A pragmatic randomized clinical trial.
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Prevention, Risk Reduction, and Hereditary Cancer
Track: Prevention, Risk Reduction, and Hereditary Cancer; Sub Track: Cancer Prevention
Abstract #10577; Poster Bd #210
Sheena Bhalla, Vijaya Natchimuthu, Jessica Lee, Urooj Wahid, Hong Zhu, Noel Santini, Travis Browning, Heidi Hamann, David Johnson, Hsienchang Chiu, Simon Lee, David Gerber

Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan.
4:30 – 6 p.m.
S102, On Demand
Poster Discussion Session
Session Title: Prevention, Risk Reduction, and Hereditary Cancer
Track: Prevention, Risk Reduction, and Hereditary Cancer; Sub Track: Hereditary Cancer Syndromes
Abstract #10515; Poster Bd #148
Anusha Chidharla, Ryan Fleer, Madison Murphy, Kelly Brunk, Jeffrey Holzbeierlein, Anup Kasi, Rahul Parikh

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
4:30 – 6 p.m.
S404, On Demand
Poster Discussion Session
Session Title: Sarcoma
Track: Sarcoma; Sub Track: Soft Tissue Tumors
Abstract #11516; Poster Bd #450
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan, Silvana Bucur, Liam Il-Young Chung, Christine 

June 4, 2023

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).
8 – 11 a.m.
Hall A, On Demand
Publication Only
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Other GI Cancer
Abstract #e16330
Sandip Patel, Elizabeth Guadarrama, Young Kwang Chae, Chih-Yi Liao, Anup Kasi, Grace Tarabay, Thomas George, Liam Chung, Gabby Lopez, Christine McLeod, Megan Othus, Helen Chen, Elad Sharon, Howard Streicher, Christopher Ryan, Charles Blanke, Razelle Kurzrock

Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer; Sub Track: Biologic Correlates
Abstract #578; Poster Bd #408
Shane Stecklein, Devin Koestler, Nanda Yellapu, Rachel Yoder, Bruce Kimler, Joshua Staley, Zachary Schmitt, Qamar Khan, Anne O'Dea, Lauren Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh Pathak, Andrew Godwin, Priyanka Sharma

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer; Sub Track: Local-Regional Therapy
Abstract #TPS623; Poster Bd #449a
Julia White, Reena Cecchini, Eleanor Harris, Eleftherios Mamounas, Daniel Stover, Patricia Ganz, Reshma Jagsi, Stewart Anderson, Carmen Bergom, Valerie Theberge, Mahmoud El-Tamer, Richard Zellars, Dean Shumway, Guang-Pei Chen, Thomas Julian, Norman Wolmark, Annabel Goodwin

Clinical validation of an activity-based enzyme assay for early stage lung cancer.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track: Lung Cancer; Sub Track: Biologic Correlates
Abstract #8533; Poster Bd #160
Paul Dempsey, Cristina-Mihaela Aparicio, Ricardo Gonzalezirias, Spencer Hantula, Mari Kagawa, Stefan Bossmann, Obdulia Covarrubias-Zambrano, Alykhan Nagji, Nirmal Veeramachaneni, Nezih Ermerak, Derya Kocakaya, Tunc Lacin, Bedrettin Yildizeli, Sara Witting Christensen Wen, Line Nederby, Torben Hansen, Ole Hilberg

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer; Sub Track: Hormone Receptor-Positive
Abstract #1076; Poster Bd #297
Erin Cobain, William Barlow, Costanza Paoletti, Mattias Bergqvist, Amy Williams, Hanna Ritzen, Rita Mehta, Julie Gralow, Gabriel Hortobagyi, Kathy Albain, Lajos Pusztai, Priyanka Sharma, Andrew Godwin, Alastair Thompson, Daniel Hayes, James Rae

How PROMs Can Reveal More About Patient Buy-in to Therapy
11:30 a.m. – 12:45 p.m.
S100bc, On Demand
Education Session
Session Title: Patient-Centric Clinical Trial Design in Genitourinary Cancers: Meaningful Endpoints, Assessments, and Outcome Measures
Track: Genitourinary Cancer—Kidney and Bladder | Clinical Trials
Elizabeth Wulff-Burchfield

June 5, 2023

Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
8 – 11 a.m.
S100a, Livestream
Oral Abstract Session
Session Title: Symptoms and Survivorship
Track: Symptoms and Survivorship; Sub Track: Health Promotion
Abstract #12001
Jennifer Ligibel, Karla Ballman, Linda McCall, Pamela Goodwin, Anna Weiss, Linda Delahanty, Catherine Alfano, Tracy Crane, Marian Neuhouser, Patricia Spears, Dawn Hershman, Electra Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Thomas Wadden, Eric Winer, Ann Partridge, Lisa Carey

A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Abstract #TPS4176; Poster Bd #494b
Yelena Janjigian, Weijing Sun, Caio Max Rocha Lima, Satish Shah, Aaron Scott, Dulabh Monga, Madappa Kundranda, Amna Sher, Philip Gold, Jordan Berlin, Manish Patel, Olatunji Alese, Erika Hamilton, Michael Cecchini, Brian Van Tine, Ben George, Rutika Mehta, Zhenzhong Xia, Caroline Germa, Nashat Gabrail

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.
8 – 11 a.m.
S100a, Livestream
Oral Abstract Session
Session Title: Symptoms and Survivorship
Track: Symptoms and Survivorship; Sub Track: Health Promotion
Abstract #LBA12007
Kathryn Weaver, Emily Dressler, Heidi Klepin, Simon Lee, Sydney Smith, Brian Wells, W. Hundley, Glenn Lesser, Chandylen Nightingale, Alyssa Throckmorton, Marcia Hernandez, Jenny Hanna, Ian Lackey, Kevin Heard, Randi Foraker

KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Pancreatic Cancer - Advanced/Metastatic Disease
Abstract #4150; Poster Bd #471
Aaron Ciner, Bach Ardalan, Yasmine Baca, Sourat Darabi, Anup Kasi, Emil Lou, Jose Azqueta, Joanne Xiu, Chadi Nabhan, Anthony Shields, Andrew Aguirre, Harshabad Singh, Rachna Shroff, Michael Pishvaian, Sanjay Goel

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Pancreatic Cancer - Local-Regional Disease
Abstract #TPS4202; Poster Bd #507b
Kim Reiss, Sung Hong, Anup Kasi, Eileen O'Reilly, Shishir Maithel, Xin Yao, Stanley Hamilton, Ben Boursi, Michael Pishvaian, Samuel Klempner, Susan Domchek, Paul Catalano, E. Gabriela Chiorean, Philip Philip, Peter O'Dwyer

A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Abstract #TPS4174; Poster Bd #493b
Andrew Ko, Mark Zalupski, Raed Al-Rajabi, Khalid Matin, Deirdre Cohen, Smitha Krishnamurthi, Brent Kreider, Jessica Box, Caroline Emery, Martin Teresk, Mary Varterasian, Martin Lee, Anna Groover, Deb Knoerzer, Rachna Shroff

Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Pancreatic Cancer - Local-Regional Disease
Abstract #: TPS4205; Poster Bd #509a
Anup Kasi, Francisco Diaz, Raed Al-Rajabi, Joaquina Baranda, Erin Carroll, Cathey Belcher, Mojtaba Olyaee, Amit Rastogi, Timothy Schmitt, Sean Kumer, Atta Nawabi, Harsh Pathak, Andrew Godwin, Mary Markiewicz, Weijing Sun

Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies; Sub Track: Acute Leukemia
Abstract #TPS7078; Poster Bd #205b
Tara Lin, Robyn Wood, Tammy Ham, Taegen Sullivan, Prasad Dandawate, Shrikant Anant, Marianne Santaguida, Paul Toren, Roy Jensen, John Taylor, Michael Baltezor, Michael Dalton, Fred Meyer, John McBride, Jay Umbreit, William McCulloch, Kathryn Vanderlaag, Joseph Wagner, Scott Weir, B. Smith

Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies; Sub Track: Acute Leukemia
Abstract #7027; Poster Bd #157
Ellen Ritchie, Tara Lin, Laura Newell, Robert Stuart, Scott Solomon, Richard Stone, Gary Schiller, Matthew Wieduwilt, Eileen Ryan, Nalina Dronamraju, Jeffrey Lancet, Jorge Cortes

Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.
8 – 11 a.m.
Hall A, On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies; Sub Track: Acute Leukemia
Abstract #: 7029; Poster Bd #159
Joshua Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Nalina Dronamraju, Stefan Faderl, Tara Lin, Geoffrey Uy, Jeffrey Lancet, Jorge Cortes

Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
11:30 a.m. – 2:30 p.m.
Oral Abstract Session
Session Title: Breast Cancer - Metastatic
Track: Hematologic Malignancies; Sub Track: Acute Leukemia
Abstract #: 1007

Qamar J. Khan, Colleen Bohnenkamp, Taylor Monson, Holly Smith, Milind Phadnis, Vinay Raja, Manana Elia, Anne O'Dea, Gregory Crane, Mark Fesen, Lauren Elizabeth Nye, Maureen Sheehan, Robert E. Pluenneke, Raed Al-Rajabi, Joaquina Baranda, Anup Kasi, Richard J. McKittrick, Laura Mitchell, Stephanie LaFaver, Priyanka Sharma

Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.

11:30 a.m. – 1 p.m.

Hall D2, Livestream
Poster Discussion Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Pancreatic Cancer - Advanced/Metastatic Disease
Abstract #4020; Poster Bd #341
Bach Ardalan, Aaron Ciner, Yasmine Baca, Sourat Darabi, Anup Kasi, Emil Lou, Jose Azqueta, Joanne Xiu, Chadi Nabhan, Anthony Shields, Andrew Aguirre, Harshabad Singh, Rachna Shroff, Michael Pishvaian, Sanjay Goel

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.
11:30 a.m. – 2:30 p.m.
Hall B1, Livestream
Oral Abstract Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer; Sub Track: Biologic Correlates
Abstract #507
Shane Stecklein, Rachel Yoder, Joshua Staley, Zachary Schmitt, Anne O'Dea, Lauren Nye, Manana Elia, Deepti Satelli, Gregory Crane, Rashna Madan, Maura O'Neil, Andrew Godwin, Roberto Salgado, Qamar Khan, Joyce O'Shaughnessy, Priyanka Sharma

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
1:15 – 2:45 p.m.
E450, On Demand
Poster Discussion Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies; Sub Track: Non-Hodgkin Lymphoma
Abstract #7509; Poster Bd #60
Caron Jacobson, Michael Hemmer, Zhen-Huan Hu, Matthew Frank, Leslie Popplewell, Nausheen Ahmed, Yi Lin, Timothy Best, Sara Beygi, Harry Miao, Christine Fu, Fang Sun, Hairong Xu, Marcelo Pasquini

Demographic predictors of successful transition to adult survivorship care for survivors of pediatric cancer.
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Pediatric Oncology
Track: Pediatric Oncology; Sub Track: Survivorship
Abstract #10050; Poster Bd #356
Renee Gilbert, Carolyn Bates, Kyla Alsman, Joy Fulbright, Becky Lowry, Eve-Lynn Nelson

Objective assessment of fatigue, sleep and insomnia in breast cancer survivors on estrogen deprivation therapy.
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Symptoms and Survivorship
Track: Symptoms and Survivorship; Sub Track: Palliative Care and Symptom Management
Abstract #TPS12145; Poster Bd #509a
Lauren Fowler, Jamie Myers, Shelby Re, Maddie Tedrick, Matthew Hudson, Joe Stephenson, Mark O'Rourke

English- and Spanish-preferring patient perspectives on managing acute care needs at two disparate health systems.
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Care Delivery and Regulatory Policy
Track: Care Delivery and Regulatory Policy; Sub Track: Care Delivery/Models of Care
Abstract #1524; Poster Bd #118
Beverly Kyalwazi, Ethan Halm, D. Mark Courtney, John Sweetenham, Navid Sadeghi, John Cox, Simon Lee, Arthur Hong

Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).
1:15 – 4:15 p.m.
Hall A, On Demand
Poster Session
Session Title: Head and Neck Cancer
Track: Head and Neck Cancer; Sub Track: Biologic Correlates
Abstract #6062; Poster Bd #54
Kartik Sehgal, Ze Zhang, Keisuke Shirai, Rondi Butler, Min Lee, Annette Molinaro, John Wiencke, Devin Koestler, Lucas Salas, Brock Christensen, Karl Kelsey, Robert Haddad

A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
3 – 4:30 p.m.
E450, On Demand
Poster Discussion Session
Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies; Sub Track: Multiple Myeloma
Abstract #8018; Poster Bd #10
Saad Usmani, Michał Mielnik, Ja Byun, Aránzazu Alonso Alonso, Al-Ola Abdallah, Mamta Garg, HANG QUACH, Chang-Ki Min, Wojciech Janowski, Enrique Ocio, Katja Weisel, Albert Oriol, Irwindeep Sandhu, Paula Rodríguez-Otero, Karthik Ramasamy, Jacqueline Egger, Danae Williams, Jie Ma, Morrys Kaisermann, Marek Hus

Polygenic risk score calibration and association with breast cancer in diverse ancestries.
3 – 6 p.m.
S100a, Livestream
Oral Abstract Session
Session Title: Prevention, Risk Reduction, and Hereditary Cancer
Track: Prevention, Risk Reduction, and Hereditary Cancer; Sub Track: Cancer Prevention
Abstract #10505
Matthew Kucera, Elisha Hughes, Brent Mabey, Brooke Hullinger, Holly Pederson, Tuya Pal, Susan Domchek, Charis Eng, Judy Garber, Ora Gordon, Jennifer Klemp, Semanti Mukherjee, Joseph Vijai, Sandhya Pruthi, Allison Kurian, Pat Whitworth, Jerry Lanchbury, Thomas Slavin, Alexander Gutin, Olufunmilayo Olopade

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).
3 – 6 p.m.
Hall D1, Livestream
Oral Abstract Session
Session Title: Melanoma/Skin Cancers
Track: Melanoma/Skin Cancers; Sub Track: Advanced/Metastatic Disease
Abstract #9511
Zeynep Eroglu, Janice Mehnert, Anita Giobbie-Hurder, Kari Kendra, Gino In, April Salama, Gary Doolittle, Jeffrey Sosman, Jennifer Valerin, Theresa Medina, Jose Lutzky, Stergios Moschos, Nikhil Khushalani, Joseph Markowitz, Naoko Takebe, Helen Chen, Laura Knight, Michael Davies, Ryan Sullivan

June 6, 2023

Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
9:45 a.m. – 12:45 p.m.
S100a, Livestream
Oral Abstract Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies; Sub Track: Non-Hodgkin Lymphoma
Abstract #7507
Swetha Kambhampati, Nausheen Ahmed, Mehdi Hamadani, Natalie Grover, Mazyar Shadman, Frederick Locke, James Gerson, Matthew Frank, Lihua Budde, Michael Wang, Zhen-Huan Hu, Ana Nunes, David Dalton, Ioana Kloos, Daniel Lee, Hairong Xu, Marcelo Pasquini, Alex Herrera

Publication Only

Energetics and Lifestyle in Inherited Syndromes (ELLIES Project): Feasibility of remote specimen collection for biomarker analysis.
Session Title: Publication Only: Prevention, Risk Reduction, and Hereditary Cancer
Track: Prevention, Risk Reduction, and Hereditary Cancer; Sub Track: Hereditary Cancer Syndromes
Abstract #e22545
Priyanka Venkatesh, Catherine Knight, Jennifer Klemp, Rajni Puri, Harsh Pathak, Clark Bloomer, Lauren Nye

Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
Session Title: Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies; Sub Track: Multiple Myeloma
Abstract #e20044
Priyanka Venkatesh, Shebli Atrash, Barry Paul, Omar Alkharabsheh, Aimaz Afrough, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Hamza Hashmi, James Davis, Al-Ola Abdallah

Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials.
Session Title: Publication Only: Health Services Research and Quality Improvement
Track: Health Services Research and Quality Improvement; Sub Track: Healthcare Equity/Access to Care
Abstract #e18633
Nausheen Ahmed, William Wesson, Dinesh Pal Mudaranthakam, Muhammad Umair Mushtaq, Al-Ola Abdallah, Forat Lutfi, Joaquina Baranda, Sunil Abhyankar, Joseph McGuirk, Marc Hoffmann

Responses in patients with AML and treated with entospletinib monotherapy.
Session Title: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies; Sub Track: Acute Leukemia
Abstract #e19010
Tara Lin, Richard Cutler, Elizabeth Olek, Luis Carvajal, Jorge DiMartino, Alison Walker

Pharmacokinetics (PK) of epacadostat in combination with sirolimus in advanced malignancy.
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy; Sub Track: New Targets and New Technologies (IO)
Abstract #e14589
Chao Huang, Takefumi Komiya, Anup Kasi, Stephen Williamson, Scott Weir, Joaquina Baranda

Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
Poster Session
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track: Lung Cancer; Sub Track: Small Cell Lung Cancer
Abstract #TPS8615; Poster Bd #234a
Aditya Juloori, Gregory Gan, Jun Zhang, Mohamed Abazeed, Jared Hara, Andrew Baschnagel, Anne Traynor, Michael Bassetti, Marina Garassino, Jyoti Patel, Steven Chmura, Christine Bestvina

Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.
Session Title: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies; Sub Track: Myeloproliferative Syndromes (MPD)
Abstract #e19080
Aleksander Chojecki, Danielle Boselli, Allison Dortilus, Issam Hamadeh, Stephanie Begley, Tommy Chen, Rupali Bose, Nikolai Podoltsev, Amer Zeidan, Nicole Balmaceda, Abdulraheem Yacoub, Jing Ai, Thomas Knight, Brittany Ragon, Nilay Shah, Srinivasa Sanikommu, James Symanowski, Ruben Mesa, Michael Grunwald

Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
Poster Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer; Sub Track: Hormone Receptor-Positive
Abstract #1059; Poster Bd #280
Lorenzo Gerratana, Yue Ren, Carolina Reduzzi, Meredith Regan, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Jane Meisel, Kathy Miller, Trevor Jolly, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Naomi Ko, Yuan Liu, Harold Burstein, Sara Tolaney, Massimo Cristofanilli, Erica Mayer

Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary; Sub Track: Pancreatic Cancer - Advanced/Metastatic Disease
Abstract #4156; Poster Bd #477
Anup Kasi, Junqiang Dai, Raed Al-Rajabi, Joaquina Baranda, Anwaar Saeed, Prabhakar Chalise, Erin Carroll, Shannon Bradbury, Stephen Hyter, Malgorzata Witek, Venkatadri Beeki, Richard McKittrick, Manidhar Reddy Lekkala, Anusha Chidharla, Sean Kumer, Timothy Schmitt, Stephen Williamson, Steven Soper, Andrew Godwin, Weijing Sun

Underline: KUCC Members
Underline & Bold: KUCC Members that Presented

April 16, 2023

SESSION PO.ET01.01 - Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1
536 / 3 - The role of CCN1 in mutant K-RAS addiction in pancreatic ductal adenocarcinoma
1:30 - 5 p.m.
Archana De, Vijayalaxmi Gupta, Amlan Das, Arnab Ghosh, Inamul Haque, Laster Lau, Sushanta K. Banerjee, Snigdha Banerjee

SESSION PO.MCB05.01 - Targeting Replication Stress and the Immune Microenvironment
302 / 4 - Loss of head and neck squamous cell carcinoma MK2 increases STING activation through increased micronuclei formation
1:30 - 5 p.m.
Colby Spiess, Grace Millington, Hannah Smith, Dakota D. D. Okwuone, Kiersten Berggren, Deri Morgan, Chris Lominska, Sufi M. Thomas, Jingxin Wang, Mary Markiewicz, Gregory N. Gan

SESSION PO.MCB08.05 - Innovative Approaches for Tumor Profiling and Data Analysis 2
243 / 7 - Long-read sequencing of pediatric cancer genomes identifies multiple clinically relevant variants
1:30 - 5 p.m.
Byunggil Yoo, Warren Cheung, Irina Pushel, Lisa Lansdon, Chengpeng Bi, Erin Guest, Tomi Pastinen, Midhat Farooqi

SESSION CTPL02 - Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents
CT009 - S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
5 – 5:15 p.m.
Kari Kendra, Shay Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M. Campbell, William Carson III, David Wada, Jose A. Plaza, Jeffrey Sosman, Gino K. IN, Alexandra Ikeguchi, John Hyngstrom, Andres Brohl, Nikhil I. Khushalani, Joseph Markowitz, George Negrea, Samer Kasbari, Gary C. Doolittle, Umang Swami, Toni Roberts, Sapna P. Patel, Elad Sharon, James Moon, Michael C. Wu, Antoni Ribas.

April 17, 2023

SESSION PO.CL01.11 - Biomarkers for Elucidation of Tumor Biology and Metastasis
2119 / 22 - Intravenous vitamin C therapy for cisplatin ineligible bladder cancer patients (CI-MIBC): Early investigation into potential pharmacodynamic biomarkers
9 a.m. – 12:30 p.m.
Benjamin L. Woolbright, Ganeshkumar Rajendran, Erika Abbott, Zeb Zacharias, Jon Houtman, Rahul Parikh, Qi Chen, Ameer Hamza, Elizabeth Wulff-Burchfield, Jeffrey M. Holzbeierlein, Jeanne Drisko, Michael D. Henry, John A. Taylor

SESSION PO.CT03.01 - Phase III and Pediatric Clinical Trials
CT089 / 17 - Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
9 a.m. – 12:30 p.m.
Giselle L. Saulner Sholler, Jacqueline Kraveka, Genevieve Bergendahl, Elizabeth Lewis, William Ferguson, Abhinav Nagulapally, Karl Dykema, Valerie Brown, Michael Isakoff, Joseph Junewick, Deanna Mitchell, Don Eslin, Virginia Harrod, William Roberts, Javier Oesterheld, Randy Wada, Jawhar Rawwas, Devang Pastakia, Kevin Ginn, Raya Saab, Kevin Bielamowicz, Jason Glover, Eugenia Chang, Gina Hanna, Daniel Enriquez, Tyler Izatt, Rebecca Halperin, Sara Byron, William Hendricks, Jeffrey Trent.

SESSION PO.ET01.02 - Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
1706 / 3 - A non-canonical MiT/TFE-dependent NRF2 program is a druggable vulnerability in multiple cancer types
9 a.m. – 12:30 p.m.
Xinbo Luo, Bart Lutterbach, Priya Pancholi, Yeon Sook Choi, Xiao Liu, Phillip Munson, Saqib Faisal, David A. Whipple, Robert A. Smith, Warren S. Weiner, David K. Johnson, Myriam Boukhali, Nicole S. Persky, Matthew G. Rees, Shunsuke Kitajima, David Barbie, Anuradha Roy, Michael Baltezor, Lian Rajewski, William McGuinness6, John Haslam, Ananthan Sadagopan, Charles H. Yoon, Cory M. Johannessen, Christine G. Lian7, Jason L. Hornick7, Srinivas R. Viswanathan, David Liu, Vicki Nienaber, Wilhelm Haas, Frank J. Schoenen, David E. Fisher, Rizwan Haq

SESSION PO.ET02.03 - New Therapeutic Targeted Agents
1585 / 8 - Targeting acid ceramidase-1 to inhibit sphingolipid metabolism and tumor growth in pancreatic ductal carcinoma
9 a.m. – 12:30 p.m.
Krishan G. Jain, Hindole Ghosh, Sangita Bhattacharyya, Anup Kasi, Ameer Hamza, Scott J. Weir, Michael VanSaun, Stefan Bossmann, Shrikant Anant, Bernhard Biersack, Prasad R. Dandawate

SESSION PO.ET03.06 - Reversal of Drug Resistance
1753 / 18 - Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy
9 a.m. – 12:30 p.m.
Lanjing Wei, Qi Zhang, Cuncong Zhong, Jeffrey Aubé, Danny Welch, Xiaoqing Wu, Liang Xu

SESSION PO.ET05.01 - Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy
1565 / 13 - Targeting of KIF11 and AURKA to improve outcomes in Ewing sarcoma
9 a.m. – 12:30 p.m.
Soumya M. Turaga, Vikalp Vishwakarma, Stacey Hembruff, Rajni Puri, Priya Sabu, Glenson Samuel, Andrew K. Godwin

SESSION PO.MCB02.02 - Autophagy, Mitochondrial Function, and Ferroptosis
1370 / 1 - Overexpression of the small GTPase Rab27B regulates autophagy flux and contributes to tumor growth in colorectal cancer
9 a.m. – 12:30 p.m.
Sahida Afroz, Ranjan Preet, Vikalp Vishwakarma, Dan A. Dixon

SESSION LBPO.CL01 - Late-Breaking Research: Clinical Research 1 / Endocrinology
LB122 / 5 - Arima-HiC sequencing accurately detects clinically relevant structural variants in pediatric leukemia samples
1:30 – 5 p.m.
Anthony Schmitt, Shadi Melnyk, Kristin Sikkink, Lisa Lansdon, Tomi Pastinen, Erin Guest, Midhat Farooqi

SESSION PO.CL01.08 - Diagnostic and Prognostic Biomarkers 3
3301 / 9 - Ultrasensitive compartment-free digital phenotyping of circulating extracellular vesicles for diagnosis of Ewing sarcoma
1:30 – 5 p.m.
Yunjie Wen, Vikalp Vishwakarma, Andrew K. Godwin, Yong Zeng

SESSION PO.CL01.10 - Early Detection Biomarkers
3351 / 26 - Identification of novel biomarkers for high grade serous ovarian cancer screening via extracellular vesicle proteomic profiling
1:30 – 5 p.m.
Camille V. Trinidad, Harsh B. Pathak, Shibo Cheng, Rashna Madan, Mihaela E. Sardiu, Leonidas E. Bantis, Yong Zeng, Andrew K. Godwin

3354 / 29 - Isolation and characterization of circulating tumor cells from ductal carcinoma in situ patients using label free technology
Brittany Rupp, Brooke Thanasiu, Neha Nagpal, Yan Hong, Dean E. Brenner, Kirsten Tuck, Kirk Herman, Fariba Behbod, Justin Colacino, Max Wicha, Sunitha Nagrath

SESSION PO.CL07.07 - Combination Immunotherapies 2
3275 / 16 - Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
1:30 – 5 p.m.
Siwen Hu-Lieskovan, James Moon, John Hyngstrom, Katie M. Campbell, Gino K. In, Theodore F. Logan, Kari L. Kendra, Ding M. Wang, Douglas B. Johnson, Gary C. Doolittle, Alan Tan, Ann W. Silk, Kenneth F. Grossmann, Christopher W. Ryan, Sapna P. Patel, Shay Bellasea, Michael C. Wu, John M. Kirkwood, Helen X. Chen, Antoni Ribas

SESSION PO.CL07.11 - Combination Immunotherapies 1
3235 / 8 - Protein kinase C is an upstream regulator of IL13Ra2 and small molecular activator enhances CAR T mediated killing
1:30 – 5 p.m.
Siddharth Subham, John D. Jeppson, Bryan Schatmeyer, Stephen J. Forman, Christine E. Brown, David Akhavan

SESSION PO.CT02.01 - Phase II Clinical Trials 1
CT167 / 29 - Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
1:30 – 5 p.m.
Joanna Rhodes, David Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Jennifer Woyach, Nicole Lamanna, Marc S. Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Maranda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato, William G. Wierda.

SESSION PO.ET02.07 - Drug Delivery Systems
2701 / 4 - pH-responsive targeted-nanoparticle releases encapsulated ERK-inhibitor effectively in the hypoxic microenvironment and sensitizes gemcitabine in pancreatic cancer cells
1:30 – 5 p.m.
Debasmita Dutta, Archana De, Raj Shankar Hazra, Pratyusha Ghosh, Mohiuddin Quadir, Snigdha Banerjee, Sushanta K. Banerjee

SESSION PO.PR01.03 - Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship
3030 / 2 - Effect of 6 months of bazedoxifene and conjugated estrogen on measures of insulin resistance in postmenopausal women at increased risk for breast cancer
1:30 – 5 p.m.
Carol J. Fabian, Erin D. Giles, Katherine L. Cook, Kandy Powers, Christy Altman, Amy Kreutzjans, Teresa Phillips, Adrian Zelenchuk, Krystal Pittman, Stephen D. Hursting, Bruce Kimler

SESSION PO.PS01.03 - Aging, Immune Factors, and Metabolomics
3005 / 1 - Pre-diagnostic methylation-based leukocyte profiles and non-small cell lung cancer risk in heavy smokers
1:30 – 5 p.m.
Laurie Grieshober, Stefan Graw, Matt J. Barnett, Gary E. Goodman, Chu Chen, Devin C. Koestler, Carmen J. Marsit, Jennifer A. Doherty

April 18, 2023

SESSION PO.BCS02.04 - Integrative Cancer Systems Biology
4318 / 16 - Cancer cell communication with macrophages prevents T cell activation during emergence of cell cycle therapy resistance
9 a.m. – 12:30 p.m.
Jason I. Griffiths, Patrick A. Cosgrove, Eric Medina Castaneda, Aritro Nath, Jinfeng Chen, Frederick R. Adler, Jeffrey T. Chang, Qamar J. Khan, Andrea H. Bild

SESSION PO.MCB10.03 - Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck
3744 / 2 - A circulating microRNA panel predicts recurrence and survival in early-stage lung adenocarcinoma
9 a.m. – 12:30 p.m.
Mei-Chee Tai, Leonidas E. Bantis, Gargy Parhy, Taketo Kato, Ichidai Tanaka, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi, Johannes F. Fahrmann, Edwin Ostrin, Kohei Yokoi, Toyofumi F. Chen-Yoshikawa, Yoshinori Hasegawa, Samir M. Hanash, Ignacio I. Wistuba, Ayumu Taguchi

SESSION PO.TB04.02 - Regulation of Invasion and Migration
3601 / 7 - Tumor MK2 signaling regulates cell migration and invasion in head and neck squamous cell carcinoma
9 a.m. – 12:30 p.m.
Dakota D. D. Okwuone,Deri Morgan, Hannah M. Smith, Grace Millington, Kiersten L. Berggren, Christopher E. Lominska, Sufi M. Thomas, Gregory N. Gan

SESSION PO.TB06.01 - Pediatric Cancer 3: Genomes and Novel Tumor Models
3551 / 2 - Single-cell characterization of pediatric T-cell acute lymphoblastic leukemia transcriptomes
9 a.m. – 12:30 p.m.
Irina Pushel, Byunggil Yoo, Daniel Louiselle, Margaret Gibson, Midhat S. Farooqi, Keith August

SESSION PO.TB11.01 - Signaling Pathways That Impact the Tumor Microenvironment
3654 / 28 - Olaparib combined with entinostat exerts differential effects on tumor-associated macrophages in tumors compared to ascites in syngeneic HR-proficient murine models of ovarian cancer
9 a.m. – 12:30 p.m.
Vijayalaxmi G. Gupta, Tyler Woodard, Simona Miceska, Bisiyao Fashemi, Sangappa Chadchan, Wendy Zhang, Katherine Roby, Andrew Wilson, Fiona Yull, Marta Crispens, Sumanta Naik, Asya Smimov, Christina Stallings, Dineo Khabele

SESSION PO.CH01.05 - High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery
5334 / 16 - Targeting the KIF15-TPX2 PPI to overcome KIF11 inhibitor resistance in epithelial ovarian cancer
1:30 – 5 p.m.
Benjamin K. Gibbs, Justin T. Douglas, Rebecca J. Wates, Peter R. McDonald, Amy M. Whitaker, Cornelius N. Ndi, Harsh B. Pathak, Laurie A. Harned, Sarah A. Neuenswander, Melinda A. Broward, Bret D. Freudenthal, Anuradha Roy, Frank J. Schoenen, Andrew K. Godwin

SESSION PO.EN01.02 - Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics
5280 / 4 - O-GlcNAcylation of progesterone receptor promotes mammary tumorigenesis
1:30 – 5 p.m.
Harmony Ivanna Saunders, Sean M. Holloran, Gloria Trinca, Chad Slawson, Christy Hagan

SESSION PO.ET01.05 - Targeting Protein Kinases and Phosphatases for Therapy 2
5020 / 12 - IRAK1 is a critical mediator of hyaluronic acid induced stemness
1:30 – 5 p.m.
David Standing, Prasad Dandawate, Jaimie Johnson, Sumedha Gunewardena, Michele T. Pritchard, Harsh Pathak, Dineo Khabele, Katherine Roby, Andrew Godwin, Roy Jensen, Scott Weir, Shrikant Anant

SESSION PO.PR02.02 - Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention
5259 / 13 - Bazedoxifene plus conjugated estrogen improves metabolic health and reduces mammary gland epithelial proliferation in an ovary intact rat model of obesity and breast cancer risk
1:30 – 5 p.m.
Ramsey M. Jenschke, Karen A. Corleto, Carol J. Fabian, Stephen D. Hursting, Bruce F. Kimler, Danilo Landrock, Tara N. Mahmood, Katherine L. Cook, Erin D. Giles

SESSION MS.BCS02.01 - Clinical Applications of Artificial Intelligence and Mathematical Oncology
5693 - Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER+ breast cancer
2:37 – 2:52 p.m.
Jason I. Griffiths, Patrick A. Cosgrove, Eric Medina Castaneda, Aritro Nath, Jinfeng Chen, Frederick R. Adler, Jeffrey T. Chang, Qamar J. Khan, Andrea H. Bild

SESSION MS.PR01.01 - Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities
2:30 – 4:30 p.m.
Chairperson and Introduction: Andrew K. Godwin

SESSION LE08 - AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
5:15 – 6 p.m.
Location: Tangerine Ballroom 2, Convention Center
Chairperson: Roy A. Jensen

April 19, 2023

SESSION PO.BCS02.02 - Integrative Spatial and Temporal Multi-omics of Cancer
6623 / 28 - Spatial organization of tumor-infiltrating lymphocytes (TILs) is prognostic for survival in triple negative breast cancer (TNBC)
9 a.m. – 12:30 p.m.
Sahil H. Patel, Germán Corredor, Rachel Yoder, Cristian Barrera, Miluska Castillo, Luis Bernabe, Joshua Staley, Shane Stecklein, Satish E. Viswanath, Carlos A. Castaneda, Priyanka Sharma, Anant Madabhushi

SESSION PO.CL07.08 - Immune Monitoring and Responses to Therapy
6675 / 14 - Integration of associations of immune profiles in peripheral blood and tumor microenvironment with bladder cancer outcomes
9 a.m. – 12:30 p.m.
Ji-Qing Chen, Lucas A. Salas, John K. Wiencke, Devin C. Koestler, Annette M. Molinaro, Angeline S. Andrew, John D. Seigne, Margaret R. Karagas, Karl T. Kelsey, Brock C. Christensen

SESSION PO.CL07.10 - Immune Checkpoints
6646 / 18 - Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer
9 a.m. – 12:30 p.m.
Qi Zhang, Lauren Dandreo, Xiaoqing Wu, Liang Xu

SESSION ADT09 - Technical Advances in Liquid Biopsy and Rare Event Detection | Novel technologies for highly efficient isolation and analysis of liquid biopsy markers for cancer disease management applications
10:15 - 11:45 a.m.
Location: Room W414, Convention Center
Presenter: Steven Soper

*The below content was pulled from currently available information on ASTRO's website as well as supplied by KU Cancer Center members.

October  23, 2022
2815 Flying over the "No Fly Zone:" Re-Irradiation of Ultracentrally Located Thoracic Tumors Utilizing Hypofractionated Stereotactic Body Radiotherapy
PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH
Category: Lung Cancer/Thoracic Malignancies
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Sunday, Oct 23 4:45 PM
Presenting Author: Crosby D. Rock MD
Authors: C. D. Rock, S. S. Sood, Y. Cao, R. C. Chen, and F. Wang

October 24, 2022
1 NRG RTOG 1005: A Phase III Trial of Hypo Fractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer
Location: Henry B. Gonzalez Convention Center, Stars at Night Ballroom
Date: Monday, Oct 24 1:30 PM
Session: PL 01 - Plenary Session
F. A. Vicini, K. Winter, G. M. Freedman, D. W. Arthur, J. A. Hayman, B. S. Rosenstein, S. M. Bentzen, A. Li, J. Lyons, J. K. Tomberlin, S. A. Seaward, S. Cheston, J. Coster, B. M. Anderson, F. E. Perera, M. M. Poppe, I. A. Petersen, J. G. Bazan Jr, J. Moughan, and J. R. White

SS 11 - GU 2 - New Insights into Post-Prostatectomy Radiotherapy
Location: Henry B. Gonzalez Convention Center, Room 214
Date: Monday, Oct 24 3:00 PM
Session Type: Scientific
Track: Genitourinary Cancer
Discussant: Ronald C. Chen MD, MPH, FASTRO

October  25, 2022
3058 Cervical Spine Setup Reproducibility Using Standard Headrests vs. Custom Headrests in Head and Neck Cancer Patients
PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Tuesday, Oct 25 2:30 PM
Category: Patient Safety
Presenting Author: Truston Bodine MD, PhD
Authors: T. Bodine, K. Guida, G. N. Gan, and C. E. Lominska

October  26, 2022
2665 Assessment of Nutritional and Imaging Biomarkers to Predict PEG Tube Placement in Non-HPV-Associated Head and Neck Patients Undergoing Concurrent Chemoradiotherapy
PQA 09 - Poster Q&A 09 - Head & Neck Cancer and Health Services Research
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 10:30 AM
Category: Head and Neck Cancer
Presenting Author: Ryan Zitter MSc
Authors: R. Zitter, R. Morse, R. G. Ganju, G. N. Gan,  Y. Cao, P. Neupane, K. Kakarala, Y. Shnayder, and C. E. Lominska

3201 Hybrid Proton-Photon Treatment Planning with Fraction Optimization
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Hao Gao, PhD
Authors: W. Li, W. Zhang, Y. Lin, R. C. Chen, and H. Gao

3283 FLASH-Enabled Proton SBRT/SRS via Simultaneous Dose and Dose Rate Optimization (SDDRO)
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Hao Gao PhD
Authors: H. Gao, Y. Lin, G. N. Gan, F. Wang, H. Li, and R. C. Chen

3305 Maximization of Peak-to-Valley Dose Ratio and Normal-Tissue Survival Fraction for Proton Minibeam Radiation Therapy
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Weijie Zhang PhD
Authors: W. Zhang, W. Li, Y. Lin, F. Wang, R. C. Chen, and H. Gao

*The below content was pulled from currently available information on ASCO's website as well as supplied by KU Cancer Center members. 

June 4, 2022
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract TPS7069:  Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 297a
Presenter: Tara L. Lin, MD, MS
Authors: Tara L. Lin, Robyn Wood, Tammy Ham, Taegen Sullivan, Sangita Bhattacharyya, Prasad Dandawate, Shrikant Anant, Marianne T Santaguida, Na Zhang, Paul Toren, Roy A. Jensen, John A. Taylor III, Michael Jay Baltezor, Michael Dalton, John McBride, Jay Nicholas Umbreit, William McCulloch, Kathryn Vanderlaag, Joseph Wagner, Scott James Weir

Abstract 7027: A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 258
Authors: Alice S. Mims, Ying Huang, Eric Eisenmann, Daelynn Buelow, Ronan T. Swords, Matthew Charles, Foster, Tara L. Lin, Maria R. Baer, Tibor Kovacsovics, Zeina Al-Mansour, Mona Stefanos, Franchesca Druggan, Timothy Chen, Ashley Yocum, Uma Borate, Brian J. Druker, Amy Burd, Ross L. Levine, Sharyn D. Baker, John C. Byrd

Abstract 7031: Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 262
Authors: Geoffrey L. Uy, Vinod A. Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald Cheung, Tara L. Lin

Abstract 7043: V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 274
Authors: James K. McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen Anthony Strickland, Amir Tahmasb Fathi, Harry Paul Erba, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald Cheung, Mark J. Levis

Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract TPS4195:  Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 162b
Presenter: Anup Kasi MD, MPH

Abstract 4047:  A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 35
Presenter: Weijing Sun, MD, FACP
Authors: Sun, W., Saeed, A., Al-Rajabi, R., Kasi, A., Veermachaneni, N., Al-Kasspooles, M., Baranda, J., Phadnis, M., Godwin, A.K., Olyaee, M., Madan, R., Nagji, A., Williamson, S. A

Poster Session: Symptoms and Survivorship
Abstract 12023: Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221.
Time: June 4, 2022 – 4:30 p.m. CDT
Location: In-Person & On Demand
Poster: 269
Authors: Ciao-Sin Chen, C-S., Zirpoli, G., McCann, S.E., Barlow, W.E., Budd, G.T., Pusztai, L., Hortobagyi, G.N., Godwin, A.K., Thompson, A., Ambrosone, C.B., Stringer, K.A., Hertz, D.L.

Poster Session: Gastrointestinal Cancer - Colorectal and Anal
Abstract 3623: Circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) assessment and recurrence risk in patients undergoing curative intent resection with or without adjuvant chemotherapy in colorectal cancer: A systematic review and meta-analysis.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 416
Authors: NA (currently unavailable on website)

Poster Session: Genitourinary Cancer—Kidney and Bladder
Abstract TPS4607: MAIN-CAV: phase III randomized trial of maintenance cabozantinib (cABO) and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001). 
Time: June 4, 2022 – 1:15 p.m. CDT
Location: In-Person & On Demand
Poster: 93b
Authors: Gupta S, Ballman KV, Galsky MD, Morris MJ, Chen R, Chan TM, Dercle L, Wen Y, Sridhar S, Al-Baghadadi T, Yen AE, Grivas P, Tan A, Baghaie S, Rosenberg JE

June 5, 2022
Poster Session: Developmental Therapeutics—Immunotherapy
Abstract 2575:  Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
Time: June 5, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 230
Presenter: Chao Hui Huang, FACP, MD

June 6, 2022
Poster Session: Breast Cancer - Local/Regional/Adjuvant
Abstract 557:  A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.
Time: June 6, 2022 - 8 a.m. CDT
Location: In-Person & On Demand 
Poster: 329
Authors: Elisha Hughes, PhD; Braden Probst, MStat; Holly Jane Pedersen, MD; Timothy Simmons, MStat; Brian Morris, BS; Susan M. Domchek, MD; Charis Eng, MD, PhD; Monique Gary, MD;
Ora Gordon, MD; Jennifer R. Klemp, PhD, MPH; Semanti Mukherjee, PhD; Kenneth Offitt, MD; Olufunmilayo I. Olopade, MD; Mark E. Robson, MD; Joseph Vijai, PhD;
Pat W. Whitworth, MD, FACS, FSSO; Susanne Wagner, PhD; Jerry S. Lanchbury, PhD; Thomas P. Slavin, MD; Alexander Gutin, PhD

Abstract 594: Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (SWOG S0800) Using Image Analysis-Based Tumor Infiltrating Lymphocyte Measurements. 
Time: June 6, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 365
Authors: Blenman, K., Fanucci, K., Bai, Y., Pelekanou, V., Nahleh, Z.A., Shafi, S., Burela, S., Barlow, W.E., Sharma, P., Thompson, A.M., Godwin, A.K., Rimm, D.L., Hortobagyi, G.N., Pusztai, L.

Poster Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract 10549:  Project BRA: Breast cancer risk assessment.
Time: June 6, 2022 - 1:15 p.m. CDT
Location: In-Person & On Demand 
Poster: 425
Presenter: Lauren Elizabeth Nye, MD
Authors: Lauren E. Nye, Sharla Smith, Catherine J. Knight, Jennifer R. Klemp

Poster Session: Health Services Research and Quality Improvement
Abstract 6542:  Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.
Time: June 6, 2022 – 1:15 p.m. CDT
Location: In-Person & On Demand
Poster: 325
Presenter: Joaquina Celebre Baranda, MD
Authors: Joaquina Celebre Baranda, Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Marie Wulff- Burchfield, Benjamin Powers, Robert E. Pluenneke, Marc Steven Hoffmann, Abdulraheem Yacoub, Anwaar Saeed, Larry R. Corum, Tara L. Lin, Weijing Sun, Margaret M. Mooney, Jeffrey Moscow, James H. Doroshow, Brittany Waters, S. Percy Ivy, Steven Gore, Roy A. Jensen

Poster Discussion Session: Breast Cancer—Local/Regional/Adjuvant
Abstract 513: Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
Time: June 6, 2022 - 1:27 p.m. CDT
Location: In-Person & Live Stream | Hall B1
Poster: 285
Presenter: Priyanka Sharma, MD
Authors: Sharma, P., Stecklein, S.R., Yoder, R., Staley, J.M., Schwensen, K., O’Dea, A., Nye, L., Elia, M., Satelli, D., Crane, G., Madan, R., O’Neil, M., Wagner, J., Larson, K., Christa Balanoff, C., Phadnis, M.A., Godwin, A.K., Salgado, R., Khan, Q.J., O’Shaughnessy, J.

Poster Discussion Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract TPS5107: Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Time: June 6, 2022 - 1:15 p.m. CDT
Location: In-Person & On-Demand
Poster: 283a
Authors: Rao A, Heller G, Ryan CJ, VanderWeele DJ, Lewis LD, Tan A, Watt C, Chen RC, Kohli M, Barata PC, Gartrell BA, Grubb R, Dueck AC, Wen Y, Morris MJ. 

On-Demand
Session Type: Publication Only
IV vitamin C with chemotherapy for cisplatin ineligible bladder cancer patients (CI-MIBC) first-stage analysis NCT04046094.
Session Title/Track: Genitourinary Cancer—Kidney and Bladder
Authors: Rahul Atul Parikh, PhD, MBBS | Others TBD (currently unavailable on website)

Acute promyelocytic leukemia: A single institution's experience.
Session Title/Track: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Authors: Joseph Bennett, Tara L. Lin, Priyanka Venkatesh, Heather Jean Male, Kenneth Byrd

Utilizing an innovative digital collaboration tool to impact shared decision making, health equity and trust with a focus on advance care planning for patients with metastatic breast cancer.
Session Title/Track: Symptoms and Survivorship
Authors: NA (currently unavailable on website)

Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.
Session Title/Track: Breast Cancer – Metastatic 
Authors: NA (currently unavailable on website)

Association of pathologic response and survival after peri-operative therapy in resected pancreatic adenocarcinoma: KU cancer center experience.
Session Title/Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Authors: NA (currently unavailable on website)

A multicenter, open-label, phase I/II study of FN-1501 in patients with advanced solid tumors and acute myeloid leukemia.
Session Title/Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Authors: NA (currently unavailable on website)

Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.
Session Title/Track: Breast Cancer—Metastatic
Authors: NA (currently unavailable on website)

A randomized phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or hormone receptor positive breast cancer.

Session Title/Track: Oral Abstract Session Breast Cancer-Metastatic

Authors:  Kevin Kalinsky, Melissa K Accordino, Cody Chiuzan, Prabhjot Mundi, Megna S Trivedi, Yelena Novik, Sandra Rie, William Gradishar, Anne O'Dea, Ruth O'Regan, Katherine D Crew, Dawn L Hershman